{ "instance": { "aimt-10q_20190630.htm": { "axisCustom": 0, "axisStandard": 20, "contextCount": 187, "dts": { "calculationLink": { "local": [ "aimt-20190630_cal.xml" ] }, "definitionLink": { "local": [ "aimt-20190630_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-eedm-def-2018-01-31.xml", "http://xbrl.fasb.org/srt/2018/elts/srt-eedm1-def-2018-01-31.xml" ] }, "inline": { "local": [ "aimt-10q_20190630.htm" ] }, "labelLink": { "local": [ "aimt-20190630_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2018/dei-doc-2018-01-31.xml", "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-doc-2018-01-31.xml" ] }, "presentationLink": { "local": [ "aimt-20190630_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-ref-2018-01-31.xml", "https://xbrl.sec.gov/dei/2018/dei-ref-2018-01-31.xml" ] }, "schema": { "local": [ "aimt-20190630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-roles-2018-01-31.xsd", "http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2018/elts/srt-types-2018-01-31.xsd", "http://xbrl.fasb.org/srt/2018/elts/srt-roles-2018-01-31.xsd", "http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-types-2018-01-31.xsd", "https://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd", "https://xbrl.sec.gov/exch/2018/exch-2018-01-31.xsd", "https://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "https://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-parts-codification-2018-01-31.xsd" ] } }, "elementCount": 494, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2018-01-31": 23, "http://www.aimmune.com/20190630": 2, "http://xbrl.sec.gov/dei/2018-01-31": 8, "total": 33 }, "keyCustom": 66, "keyStandard": 323, "memberCustom": 16, "memberStandard": 33, "nsprefix": "aimt", "nsuri": "http://www.aimmune.com/20190630", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_20190101_20190630", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.aimmune.com/20190630/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_20190101_20190630", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_20190101_20190630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100090 - Disclosure - Balance Sheet Components", "role": "http://www.aimmune.com/20190630/taxonomy/role/DisclosureBalanceSheetComponents", "shortName": "Balance Sheet Components", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_20190101_20190630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_20190101_20190630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100100 - Disclosure - Long-Term Debt, Net of Discounts", "role": "http://www.aimmune.com/20190630/taxonomy/role/DisclosureLongTermDebtNetOfDiscounts", "shortName": "Long-Term Debt, Net of Discounts", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_20190101_20190630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_20190101_20190630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100110 - Disclosure - Commitments and Contingencies", "role": "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_20190101_20190630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_20190101_20190630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100120 - Disclosure - Stock-Based Compensation", "role": "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensation", "shortName": "Stock-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_20190101_20190630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_20190101_20190630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100130 - Disclosure - Net Loss per Share", "role": "http://www.aimmune.com/20190630/taxonomy/role/DisclosureNetLossPerShare", "shortName": "Net Loss per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_20190101_20190630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_20190101_20190630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100140 - Disclosure - Related Party Transaction", "role": "http://www.aimmune.com/20190630/taxonomy/role/DisclosureRelatedPartyTransaction", "shortName": "Related Party Transaction", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_20190101_20190630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_20190101_20190630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100150 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://www.aimmune.com/20190630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_20190101_20190630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_20190101_20190630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100160 - Disclosure - Available-for-Sale Securities and Fair Value Measurements (Tables)", "role": "http://www.aimmune.com/20190630/taxonomy/role/DisclosureAvailableForSaleSecuritiesAndFairValueMeasurementsTables", "shortName": "Available-for-Sale Securities and Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_20190101_20190630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_20190101_20190630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100170 - Disclosure - Balance Sheet Components (Tables)", "role": "http://www.aimmune.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsTables", "shortName": "Balance Sheet Components (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_20190101_20190630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_20190101_20190630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100180 - Disclosure - Long-Term Debt, Net of Discounts (Tables)", "role": "http://www.aimmune.com/20190630/taxonomy/role/DisclosureLongTermDebtNetOfDiscountsTables", "shortName": "Long-Term Debt, Net of Discounts (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_20190101_20190630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_20190630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100010 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS", "role": "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_20190630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_20190101_20190630", "decimals": null, "first": true, "lang": "en-US", "name": "aimt:OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100190 - Disclosure - Commitments and Contingencies (Tables)", "role": "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesTables", "shortName": "Commitments and Contingencies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_20190101_20190630", "decimals": null, "first": true, "lang": "en-US", "name": "aimt:OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_20190101_20190630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100200 - Disclosure - Stock-Based Compensation (Tables)", "role": "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationTables", "shortName": "Stock-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_20190101_20190630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_20190101_20190630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100210 - Disclosure - Net Loss per Share (Tables)", "role": "http://www.aimmune.com/20190630/taxonomy/role/DisclosureNetLossPerShareTables", "shortName": "Net Loss per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_20190101_20190630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_20190401_20190630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100220 - Disclosure - Formation and Business of the Company - Additional Information (Details)", "role": "http://www.aimmune.com/20190630/taxonomy/role/DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails", "shortName": "Formation and Business of the Company - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R24": { "firstAnchor": { "ancestors": [ "p", "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_20190101_20190630", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "U_aimtSegment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100230 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)", "role": "http://www.aimmune.com/20190630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_20190101_20190630", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "U_aimtSegment", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_20190630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100240 - Disclosure - Available-for-Sale Securities and Fair Value Measurements - Summary of Financial Instruments Measured at Fair Value on a Recurring Basis (Details)", "role": "http://www.aimmune.com/20190630/taxonomy/role/DisclosureAvailableForSaleSecuritiesAndFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails", "shortName": "Available-for-Sale Securities and Fair Value Measurements - Summary of Financial Instruments Measured at Fair Value on a Recurring Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "ix:continuation", "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20190630", "decimals": "-3", "lang": null, "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount", "p", "ix:continuation", "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_20190630", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100250 - Disclosure - Available-for-Sale Securities and Fair Value Measurements - Additional Information (Details)", "role": "http://www.aimmune.com/20190630/taxonomy/role/DisclosureAvailableForSaleSecuritiesAndFairValueMeasurementsAdditionalInformationDetails", "shortName": "Available-for-Sale Securities and Fair Value Measurements - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_20190101_20190630", "decimals": null, "lang": "en-US", "name": "aimt:AvailableForSaleSecuritiesMaturitiesPeriod", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_20190630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100260 - Disclosure - Available-for-Sale Securities and Fair Value Measurements - Summary of Aggregate Market Value, Cost Basis, and Gross Unrealized Gains and Losses of Available for Sale Investments by Security Type (Details)", "role": "http://www.aimmune.com/20190630/taxonomy/role/DisclosureAvailableForSaleSecuritiesAndFairValueMeasurementsSummaryOfAggregateMarketValueCostBasisAndGrossUnrealizedGainsAndLossesOfAvailableForSaleInvestmentsBySecurityTypeDetails", "shortName": "Available-for-Sale Securities and Fair Value Measurements - Summary of Aggregate Market Value, Cost Basis, and Gross Unrealized Gains and Losses of Available for Sale Investments by Security Type (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_20190630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_20190630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100270 - Disclosure - Balance Sheet Components - Summary of Property and Equipment, Net (Details)", "role": "http://www.aimmune.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails", "shortName": "Balance Sheet Components - Summary of Property and Equipment, Net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_20190630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_20190630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100280 - Disclosure - Balance Sheet Components - Summary of Accrued Liabilities (Details)", "role": "http://www.aimmune.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails", "shortName": "Balance Sheet Components - Summary of Accrued Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_20190630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_20190630", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD_xbrlishares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100020 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "role": "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_20190630", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD_xbrlishares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_20190101_20190630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PaymentsOfDebtIssuanceCosts", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100290 - Disclosure - Long-Term Debt, Net of Discounts - Additional Information (Details)", "role": "http://www.aimmune.com/20190630/taxonomy/role/DisclosureLongTermDebtNetOfDiscountsAdditionalInformationDetails", "shortName": "Long-Term Debt, Net of Discounts - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_us-gaapLineOfCreditFacilityAxis_aimtKKRLoansMember_20190131", "decimals": "INF", "lang": null, "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_20190630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100300 - Disclosure - Long-Term Debt, Net of Discounts - Schedule of Short-term and Long-term Debt Obligations (Details)", "role": "http://www.aimmune.com/20190630/taxonomy/role/DisclosureLongTermDebtNetOfDiscountsScheduleOfShortTermAndLongTermDebtObligationsDetails", "shortName": "Long-Term Debt, Net of Discounts - Schedule of Short-term and Long-term Debt Obligations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_20190630", "decimals": "-3", "lang": null, "name": "aimt:DebtInstrumentCarryingAmountNoncurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_20190630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100310 - Disclosure - Long-Term Debt, Net of Discounts - Schedule of Future Principal Payments of Long-Term Debt (Details)", "role": "http://www.aimmune.com/20190630/taxonomy/role/DisclosureLongTermDebtNetOfDiscountsScheduleOfFuturePrincipalPaymentsOfLongTermDebtDetails", "shortName": "Long-Term Debt, Net of Discounts - Schedule of Future Principal Payments of Long-Term Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_20190630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "us-gaap:LesseeFinanceLeaseDescription", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_20190101_20190630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100320 - Disclosure - Commitments and Contingencies - Additional Information (Details)", "role": "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "shortName": "Commitments and Contingencies - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:LesseeFinanceLeaseDescription", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_20190101_20190630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "aimt:OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_20190630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100330 - Disclosure - Commitments and Contingencies - Schedule of Maturities of Operating Lease Liabilities (Details)", "role": "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails", "shortName": "Commitments and Contingencies - Schedule of Maturities of Operating Lease Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "aimt:OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_20190630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_20190401_20190630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100350 - Disclosure - Commitments and Contingencies - Component of Lease Costs Included in Condensed Consolidated Statements of Income (Details)", "role": "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesComponentOfLeaseCostsIncludedInCondensedConsolidatedStatementsOfIncomeDetails", "shortName": "Commitments and Contingencies - Component of Lease Costs Included in Condensed Consolidated Statements of Income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_20190401_20190630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "aimt:ScheduleOfOtherInformationRelatedToOperatingAndFinanceLease", "ix:continuation", "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_20190101_20190630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100360 - Disclosure - Commitments and Contingencies - Schedule of Other Information Related to Operating Lease (Details)", "role": "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOtherInformationRelatedToOperatingLeaseDetails", "shortName": "Commitments and Contingencies - Schedule of Other Information Related to Operating Lease (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "aimt:ScheduleOfOtherInformationRelatedToOperatingAndFinanceLease", "ix:continuation", "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_20190101_20190630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_20181231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100370 - Disclosure - Commitments and Contingencies - Schedule of Future Aggregate Minimum Lease Payments Calculated under ASC 840 (Details)", "role": "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureAggregateMinimumLeasePaymentsCalculatedUnderASC840Details", "shortName": "Commitments and Contingencies - Schedule of Future Aggregate Minimum Lease Payments Calculated under ASC 840 (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_20181231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_srtCounterpartyNameAxis_aimtArcherDanielsMidlandCompanyMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20180131", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100390 - Disclosure - Stock-Based Compensation - Additional Information (Details)", "role": "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails", "shortName": "Stock-Based Compensation - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_srtCounterpartyNameAxis_aimtArcherDanielsMidlandCompanyMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20180131", "decimals": null, "lang": "en-US", "name": "aimt:ShareBasedGoodsAndNonemployeeServicesTransactionStockholdersEquityVestingPeriod", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_20181231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100400 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)", "role": "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails", "shortName": "Stock-Based Compensation - Summary of Stock Option Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_20190101_20190630", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_20190401_20190630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100030 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Unaudited)", "role": "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSUnaudited", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_20190401_20190630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_aimtTwoThousandFifteenPlanMember_20181231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100410 - Disclosure - Stock-Based Compensation - Restricted Stock Unit Activity (Details)", "role": "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationRestrictedStockUnitActivityDetails", "shortName": "Stock-Based Compensation - Restricted Stock Unit Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_aimtTwoThousandFifteenPlanMember_20181231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_srtCounterpartyNameAxis_aimtArcherDanielsMidlandCompanyMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190401_20190630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionStockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100420 - Disclosure - Stock-Based Compensation - Summary of Stock-based Compensation Expense Recognized (Details)", "role": "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseRecognizedDetails", "shortName": "Stock-Based Compensation - Summary of Stock-based Compensation Expense Recognized (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_srtCounterpartyNameAxis_aimtArcherDanielsMidlandCompanyMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190401_20190630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionStockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_20190401_20190630", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100430 - Disclosure - Stock-Based Compensation - Schedule of Weighted Average Assumptions to Fair Value of Stock Options (Details)", "role": "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfWeightedAverageAssumptionsToFairValueOfStockOptionsDetails", "shortName": "Stock-Based Compensation - Schedule of Weighted Average Assumptions to Fair Value of Stock Options (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_20190401_20190630", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_20190401_20190630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100440 - Disclosure - Stock-Based Compensation - Summary of Stock-based Compensation Expense Net of Estimated Forfeitures (Details)", "role": "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseNetOfEstimatedForfeituresDetails", "shortName": "Stock-Based Compensation - Summary of Stock-based Compensation Expense Net of Estimated Forfeitures (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_20190401_20190630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100450 - Disclosure - Stock-Based Compensation - Summary of Unrecognized Stock-Based Compensation Expense and Expected Period (Details)", "role": "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfUnrecognizedStockBasedCompensationExpenseAndExpectedPeriodDetails", "shortName": "Stock-Based Compensation - Summary of Unrecognized Stock-Based Compensation Expense and Expected Period (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20190401_20190630", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100460 - Disclosure - Net Loss per Share - Schedule of Antidilutive Securities Excluded from Computation of Diluted Net Loss per Share (Details)", "role": "http://www.aimmune.com/20190630/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails", "shortName": "Net Loss per Share - Schedule of Antidilutive Securities Excluded from Computation of Diluted Net Loss per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20190401_20190630", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_aimtMyHealthTeamsMember_20190401_20190630", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100470 - Disclosure - Related Party Transaction - Additional Information (Details)", "role": "http://www.aimmune.com/20190630/taxonomy/role/DisclosureRelatedPartyTransactionAdditionalInformationDetails", "shortName": "Related Party Transaction - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_aimtMyHealthTeamsMember_20190401_20190630", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_20171231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100040 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited)", "role": "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_20180101_20180331", "decimals": "-3", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_20190101_20190630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100050 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)", "role": "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_20190101_20190630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_20190101_20190630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100060 - Disclosure - Formation and Business of the Company", "role": "http://www.aimmune.com/20190630/taxonomy/role/DisclosureFormationAndBusinessOfCompany", "shortName": "Formation and Business of the Company", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_20190101_20190630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_20190101_20190630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100070 - Disclosure - Summary of Significant Accounting Policies", "role": "http://www.aimmune.com/20190630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_20190101_20190630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_20190101_20190630", "decimals": null, "first": true, "lang": "en-US", "name": "aimt:DebtSecuritiesAvailableForSaleTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100080 - Disclosure - Available-for-Sale Securities and Fair Value Measurements", "role": "http://www.aimmune.com/20190630/taxonomy/role/DisclosureAvailableForSaleSecuritiesAndFairValueMeasurements", "shortName": "Available-for-Sale Securities and Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aimt-10q_20190630.htm", "contextRef": "C_0001631650_20190101_20190630", "decimals": null, "first": true, "lang": "en-US", "name": "aimt:DebtSecuritiesAvailableForSaleTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 51, "tag": { "aimt_AR101CommercialSupplyRequirementsForReleaseTestingMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "AR101 commercial supply requirements for release testing.", "label": "A R101 Commercial Supply Requirements For Release Testing [Member]", "terseLabel": "AR101 Commercial Supply Requirements for Release Testing" } } }, "localname": "AR101CommercialSupplyRequirementsForReleaseTestingMember", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "aimt_AR101CommercialSupplyRequirementsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "AR101 Commercial supply requirements.", "label": "A R101 Commercial Supply Requirements [Member]", "terseLabel": "AR101 Commercial Supply Requirements" } } }, "localname": "AR101CommercialSupplyRequirementsMember", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "aimt_AccruedExitFeePayment": { "auth_ref": [], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureLongTermDebtNetOfDiscountsScheduleOfShortTermAndLongTermDebtObligationsDetails": { "order": 10030.0, "parentTag": "us-gaap_LongTermDebtNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accrued exit fee payment.", "label": "Accrued Exit Fee Payment", "terseLabel": "Accrued exit fee payment" } } }, "localname": "AccruedExitFeePayment", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureLongTermDebtNetOfDiscountsScheduleOfShortTermAndLongTermDebtObligationsDetails" ], "xbrltype": "monetaryItemType" }, "aimt_AccruedLiabilitiesResearchAndDevelopmentCurrent": { "auth_ref": [], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails": { "order": 10020.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accrued liabilities research and development current.", "label": "Accrued Liabilities Research And Development Current", "terseLabel": "Research and development" } } }, "localname": "AccruedLiabilitiesResearchAndDevelopmentCurrent", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "aimt_AnnualPurchaseCommitmentsBeginningYear": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Annual purchase commitments beginning year.", "label": "Annual Purchase Commitments Beginning Year", "terseLabel": "Annual purchase commitments beginning year" } } }, "localname": "AnnualPurchaseCommitmentsBeginningYear", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "gYearItemType" }, "aimt_AnnualPurchaseCommitmentsEndingYear": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Annual purchase commitments ending year.", "label": "Annual Purchase Commitments Ending Year", "terseLabel": "Annual purchase commitments ending year" } } }, "localname": "AnnualPurchaseCommitmentsEndingYear", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "gYearItemType" }, "aimt_ArcherDanielsMidlandCompanyMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Archer Daniels Midland Company.", "label": "Archer Daniels Midland Company [Member]", "terseLabel": "Archer Daniels Midland Company" } } }, "localname": "ArcherDanielsMidlandCompanyMember", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseRecognizedDetails" ], "xbrltype": "domainItemType" }, "aimt_AvailableForSaleSecuritiesMaturitiesPeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Available for sale securities maturities period.", "label": "Available For Sale Securities Maturities Period", "terseLabel": "Available-for-sale securities, maturities period" } } }, "localname": "AvailableForSaleSecuritiesMaturitiesPeriod", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureAvailableForSaleSecuritiesAndFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "aimt_CapitalLeaseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Capital lease.", "label": "Capital Lease [Member]", "terseLabel": "Leased Equipment" } } }, "localname": "CapitalLeaseMember", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "aimt_CashAndMoneyMarketFundsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cash and money market funds.", "label": "Cash And Money Market Funds [Member]", "terseLabel": "Cash and Money Market Funds" } } }, "localname": "CashAndMoneyMarketFundsMember", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureAvailableForSaleSecuritiesAndFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "aimt_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cash paid for amounts included in measurement of lease liabilities.", "label": "Cash Paid For Amounts Included In Measurement Of Lease Liabilities [Abstract]", "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities" } } }, "localname": "CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOtherInformationRelatedToOperatingLeaseDetails" ], "xbrltype": "stringItemType" }, "aimt_CertainKeyEmployeesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Certain key employees.", "label": "Certain Key Employees [Member]", "terseLabel": "Certain Key Employees" } } }, "localname": "CertainKeyEmployeesMember", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "aimt_CommitmentsAndContingenciesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commitments and contingencies.", "label": "Commitments And Contingencies [Line Items]", "terseLabel": "Commitments And Contingencies [Line Items]" } } }, "localname": "CommitmentsAndContingenciesLineItems", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "aimt_CommitmentsAndContingenciesTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commitments and contingencies.", "label": "Commitments And Contingencies [Table]", "terseLabel": "Commitments And Contingencies [Table]" } } }, "localname": "CommitmentsAndContingenciesTable", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "aimt_ContractualObligationCurrent": { "auth_ref": [], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureAggregateMinimumLeasePaymentsCalculatedUnderASC840Details2": { "order": 10010.0, "parentTag": "aimt_ContractualObligationPresentValueOfNetMinimumPayments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Contractual obligation current.", "label": "Contractual Obligation Current", "negatedLabel": "Less: current portion" } } }, "localname": "ContractualObligationCurrent", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureAggregateMinimumLeasePaymentsCalculatedUnderASC840Details" ], "xbrltype": "monetaryItemType" }, "aimt_ContractualObligationInterestIncludedInPayments": { "auth_ref": [], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureAggregateMinimumLeasePaymentsCalculatedUnderASC840Details": { "order": 10020.0, "parentTag": "aimt_ContractualObligationPresentValueOfNetMinimumPayments", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Contractual obligation interest included in payments.", "label": "Contractual Obligation Interest Included In Payments", "negatedLabel": "Less: amount representing interest" } } }, "localname": "ContractualObligationInterestIncludedInPayments", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureAggregateMinimumLeasePaymentsCalculatedUnderASC840Details" ], "xbrltype": "monetaryItemType" }, "aimt_ContractualObligationNoncurrent": { "auth_ref": [], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureAggregateMinimumLeasePaymentsCalculatedUnderASC840Details2": { "order": 10020.0, "parentTag": "aimt_ContractualObligationPresentValueOfNetMinimumPayments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Contractual obligation noncurrent.", "label": "Contractual Obligation Noncurrent", "terseLabel": "Long-term lease liabilities" } } }, "localname": "ContractualObligationNoncurrent", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureAggregateMinimumLeasePaymentsCalculatedUnderASC840Details" ], "xbrltype": "monetaryItemType" }, "aimt_ContractualObligationPresentValueOfNetMinimumPayments": { "auth_ref": [], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureAggregateMinimumLeasePaymentsCalculatedUnderASC840Details": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureAggregateMinimumLeasePaymentsCalculatedUnderASC840Details2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Contractual obligation present value of net minimum payments.", "label": "Contractual Obligation Present Value Of Net Minimum Payments", "totalLabel": "Value of lease liabilities under ASC 840" } } }, "localname": "ContractualObligationPresentValueOfNetMinimumPayments", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureAggregateMinimumLeasePaymentsCalculatedUnderASC840Details" ], "xbrltype": "monetaryItemType" }, "aimt_CoreRxIncorporatedMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "CoreRx incorporated.", "label": "Core Rx Incorporated [Member]", "terseLabel": "CoreRx, Inc." } } }, "localname": "CoreRxIncorporatedMember", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "aimt_DebtInstrumentCarryingAmountCurrent": { "auth_ref": [], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureLongTermDebtNetOfDiscountsScheduleOfShortTermAndLongTermDebtObligationsDetails": { "order": 10050.0, "parentTag": "aimt_DebtInstrumentCarryingAmountNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Debt instrument carrying amount current.", "label": "Debt Instrument Carrying Amount Current", "terseLabel": "Less: Current portion of long-term debt" } } }, "localname": "DebtInstrumentCarryingAmountCurrent", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureLongTermDebtNetOfDiscountsScheduleOfShortTermAndLongTermDebtObligationsDetails" ], "xbrltype": "monetaryItemType" }, "aimt_DebtInstrumentCarryingAmountNoncurrent": { "auth_ref": [], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureLongTermDebtNetOfDiscountsScheduleOfShortTermAndLongTermDebtObligationsDetails": { "order": 10010.0, "parentTag": "us-gaap_LongTermDebtNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Debt instrument carrying amount noncurrent.", "label": "Debt Instrument Carrying Amount Noncurrent", "totalLabel": "Long-term debt, net of current portion" } } }, "localname": "DebtInstrumentCarryingAmountNoncurrent", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureLongTermDebtNetOfDiscountsScheduleOfShortTermAndLongTermDebtObligationsDetails" ], "xbrltype": "monetaryItemType" }, "aimt_DebtInstrumentNumberOfTranches": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt instrument number of tranches.", "label": "Debt Instrument Number Of Tranches", "terseLabel": "Debt instrument number of tranches" } } }, "localname": "DebtInstrumentNumberOfTranches", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureLongTermDebtNetOfDiscountsAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "aimt_DebtInstrumentPrepaymentFeePercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt instrument prepayment fee percentage.", "label": "Debt Instrument Prepayment Fee Percentage", "terseLabel": "Loan exit fee percentage" } } }, "localname": "DebtInstrumentPrepaymentFeePercentage", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureLongTermDebtNetOfDiscountsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "aimt_DebtInstrumentPrepaymentFeePercentageAfterYearFive": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt instrument prepayment fee percentage after year five.", "label": "Debt Instrument Prepayment Fee Percentage After Year Five", "terseLabel": "Loan prepayment fee percentage, thereafter" } } }, "localname": "DebtInstrumentPrepaymentFeePercentageAfterYearFive", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureLongTermDebtNetOfDiscountsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "aimt_DebtInstrumentPrepaymentFeePercentageYearFive": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt instrument prepayment fee percentage year five.", "label": "Debt Instrument Prepayment Fee Percentage Year Five", "terseLabel": "Loan prepayment fee percentage, after January 3, 2022 but on or prior to January 3, 2023" } } }, "localname": "DebtInstrumentPrepaymentFeePercentageYearFive", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureLongTermDebtNetOfDiscountsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "aimt_DebtInstrumentPrepaymentFeePercentageYearFour": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt instrument prepayment fee percentage year four.", "label": "Debt Instrument Prepayment Fee Percentage Year Four", "terseLabel": "Loan prepayment fee percentage, after January 3, 2021 but on or prior to January 3, 2022" } } }, "localname": "DebtInstrumentPrepaymentFeePercentageYearFour", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureLongTermDebtNetOfDiscountsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "aimt_DebtIssuanceCostsDiscountAndInterestPayable": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Debt issuance costs, discount and interest payable.", "label": "Debt Issuance Costs Discount And Interest Payable", "terseLabel": "Debt issuance costs, discount and interest payable" } } }, "localname": "DebtIssuanceCostsDiscountAndInterestPayable", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "aimt_DebtSecuritiesAvailableForSaleTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt securities available for sale.", "label": "Debt Securities Available For Sale [Text Block]", "terseLabel": "Available-for-Sale Securities and Fair Value Measurements" } } }, "localname": "DebtSecuritiesAvailableForSaleTextBlock", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureAvailableForSaleSecuritiesAndFairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "aimt_DocumentAndEntityInformationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Document and entity information.", "label": "Document And Entity Information [Abstract]" } } }, "localname": "DocumentAndEntityInformationAbstract", "nsuri": "http://www.aimmune.com/20190630", "xbrltype": "stringItemType" }, "aimt_EmployeeStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Employee stock purchase plan.", "label": "Employee Stock Purchase Plan [Member]", "terseLabel": "ESPP" } } }, "localname": "EmployeeStockPurchasePlanMember", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfUnrecognizedStockBasedCompensationExpenseAndExpectedPeriodDetails" ], "xbrltype": "domainItemType" }, "aimt_FormerExecutiveMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Former executive.", "label": "Former Executive [Member]", "terseLabel": "Former Executive" } } }, "localname": "FormerExecutiveMember", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "aimt_KKRLoansMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "KKR loans.", "label": "K K R Loans [Member]", "terseLabel": "KKR Loans" } } }, "localname": "KKRLoansMember", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureLongTermDebtNetOfDiscountsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "aimt_LesseeOperatingAndFinanceLeasesRemainingLeaseTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lessee operating and finance leases remaining lease term.", "label": "Lessee Operating And Finance Leases Remaining Lease Term", "terseLabel": "Remaining lease terms" } } }, "localname": "LesseeOperatingAndFinanceLeasesRemainingLeaseTerm", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "aimt_LesseeOperatingLeaseLeaseNotYetCommencedAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Lessee, operating lease, lease not yet commenced, amount.", "label": "Lessee Operating Lease Lease Not Yet Commenced Amount", "terseLabel": "Additional operating leases, not yet commenced, amount" } } }, "localname": "LesseeOperatingLeaseLeaseNotYetCommencedAmount", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "aimt_LineOfCreditFacilityPrepaymentPremiumAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Line of credit facility, prepayment premium amount.", "label": "Line Of Credit Facility Prepayment Premium Amount", "terseLabel": "Line of credit facility, prepayment premium amount" } } }, "localname": "LineOfCreditFacilityPrepaymentPremiumAmount", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureLongTermDebtNetOfDiscountsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "aimt_LineOfCreditFacilityProceedsReceivableUponClosingOfTransaction": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Line of credit facility, proceeds receivable upon closing of transaction.", "label": "Line Of Credit Facility Proceeds Receivable Upon Closing Of Transaction", "terseLabel": "Loan agreement, proceeds receivable upon closing of transaction" } } }, "localname": "LineOfCreditFacilityProceedsReceivableUponClosingOfTransaction", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureLongTermDebtNetOfDiscountsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "aimt_LineOfCreditFacilityProceedsReceivableUponFDAApproval": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Line of credit facility, proceeds receivable upon FDA approval.", "label": "Line Of Credit Facility Proceeds Receivable Upon F D A Approval", "terseLabel": "Loan agreement, proceeds receivable upon FDA approval" } } }, "localname": "LineOfCreditFacilityProceedsReceivableUponFDAApproval", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureLongTermDebtNetOfDiscountsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "aimt_LineOfCreditFacilityWithoutRegulatoryApprovalExpirationDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line of credit facility without regulatory approval expiration date.", "label": "Line Of Credit Facility Without Regulatory Approval Expiration Date", "terseLabel": "Line of credit facility without regulatory approval expiration date" } } }, "localname": "LineOfCreditFacilityWithoutRegulatoryApprovalExpirationDate", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureLongTermDebtNetOfDiscountsAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "aimt_LongTermPurchaseCommitmentExpirationDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Long term purchase commitment expiration date.", "label": "Long Term Purchase Commitment Expiration Date", "terseLabel": "Long-term purchase commitment expiration date" } } }, "localname": "LongTermPurchaseCommitmentExpirationDate", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "aimt_LongTermPurchaseCommitmentOptionalExtensionPeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The optional extension period in a long-term purchase commitment.", "label": "Long Term Purchase Commitment Optional Extension Period", "terseLabel": "Long-term purchase commitment, optional extension period" } } }, "localname": "LongTermPurchaseCommitmentOptionalExtensionPeriod", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "aimt_LongTermPurchaseCommitmentRenewalTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Long-term purchase commitment renewal term.", "label": "Long Term Purchase Commitment Renewal Term", "terseLabel": "Long-term purchase commitment renewal term" } } }, "localname": "LongTermPurchaseCommitmentRenewalTerm", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "aimt_LongTermPurchaseCommitmentRestatedAgreementEffectivePeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Long-term purchase commitment, restated agreement effective period.", "label": "Long Term Purchase Commitment Restated Agreement Effective Period", "terseLabel": "Long-term purchase commitment, restated agreement effective period after first delivery" } } }, "localname": "LongTermPurchaseCommitmentRestatedAgreementEffectivePeriod", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "aimt_MarketableSecuritiesUnrealizedLossesPositionMaximumPeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Marketable securities unrealized losses position maximum period.", "label": "Marketable Securities Unrealized Losses Position Maximum Period", "terseLabel": "Marketable securities unrealized losses position maximum period" } } }, "localname": "MarketableSecuritiesUnrealizedLossesPositionMaximumPeriod", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureAvailableForSaleSecuritiesAndFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "aimt_MichaelFoodsIncorporatedMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Michael foods, incorporated.", "label": "Michael Foods Incorporated [Member]", "terseLabel": "Michael Foods, Inc." } } }, "localname": "MichaelFoodsIncorporatedMember", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "aimt_MyHealthTeamsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "My Health teams.", "label": "My Health Teams [Member]", "terseLabel": "MyHealth Teams" } } }, "localname": "MyHealthTeamsMember", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureRelatedPartyTransactionAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "aimt_NonCashInterestExpense": { "auth_ref": [], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 10150.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Non-cash interest expense.", "label": "Non Cash Interest Expense", "terseLabel": "Non-cash interest expense" } } }, "localname": "NonCashInterestExpense", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "aimt_NumberOfTranchesForVestingOfShares": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of tranches for vesting of shares.", "label": "Number Of Tranches For Vesting Of Shares", "terseLabel": "Number of tranches for vesting of shares" } } }, "localname": "NumberOfTranchesForVestingOfShares", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "aimt_NumberOfYearsForPurchaseCommitmentPercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of years for purchase commitment percentage.", "label": "Number Of Years For Purchase Commitment Percentage", "terseLabel": "Number of years for minimum supply percentage after approval" } } }, "localname": "NumberOfYearsForPurchaseCommitmentPercentage", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "aimt_OperatingAndFinanceLeaseLiability": { "auth_ref": [], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails2": { "order": 10020.0, "parentTag": "aimt_OperatingAndFinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Operating and finance lease liability.", "label": "Operating And Finance Lease Liability", "totalLabel": "Present value of lease liabilities" } } }, "localname": "OperatingAndFinanceLeaseLiability", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "aimt_OperatingAndFinanceLeaseLiabilityCurrent": { "auth_ref": [], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": { "order": 10010.0, "parentTag": "aimt_OperatingAndFinanceLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Operating and finance lease liability current.", "label": "Operating And Finance Lease Liability Current", "negatedLabel": "Less: current portion" } } }, "localname": "OperatingAndFinanceLeaseLiabilityCurrent", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "aimt_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Operating and finance lease, liability, maturity.", "label": "Operating And Finance Lease Liability Maturity Table [Text Block]", "terseLabel": "Schedule of Maturities of Operating Lease Liabilities" } } }, "localname": "OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "aimt_OperatingAndFinanceLeaseLiabilityNoncurrent": { "auth_ref": [], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": { "order": 10020.0, "parentTag": "aimt_OperatingAndFinanceLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Operating and finance lease liability noncurrent.", "label": "Operating And Finance Lease Liability Noncurrent", "terseLabel": "Long-term lease liabilities" } } }, "localname": "OperatingAndFinanceLeaseLiabilityNoncurrent", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "aimt_OperatingAndFinanceLeaseLiabilityPaymentsDue": { "auth_ref": [], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Operating and finance lease liability payments due.", "label": "Operating And Finance Lease Liability Payments Due", "totalLabel": "Total lease payments" } } }, "localname": "OperatingAndFinanceLeaseLiabilityPaymentsDue", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "aimt_OperatingAndFinanceLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": { "order": 10080.0, "parentTag": "aimt_OperatingAndFinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Operating and finance lease liability payments due after year five.", "label": "Operating And Finance Lease Liability Payments Due After Year Five", "terseLabel": "Remaining Lease Payments, Thereafter" } } }, "localname": "OperatingAndFinanceLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "aimt_OperatingAndFinanceLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": { "order": 10070.0, "parentTag": "aimt_OperatingAndFinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Operating and finance lease liability payments due year five.", "label": "Operating And Finance Lease Liability Payments Due Year Five", "terseLabel": "Remaining Lease Payments, 2023" } } }, "localname": "OperatingAndFinanceLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "aimt_OperatingAndFinanceLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": { "order": 10060.0, "parentTag": "aimt_OperatingAndFinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Operating and finance lease liability payments due year four.", "label": "Operating And Finance Lease Liability Payments Due Year Four", "terseLabel": "Remaining Lease Payments, 2022" } } }, "localname": "OperatingAndFinanceLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "aimt_OperatingAndFinanceLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": { "order": 10050.0, "parentTag": "aimt_OperatingAndFinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Operating and finance lease liability payments due year three.", "label": "Operating And Finance Lease Liability Payments Due Year Three", "terseLabel": "Remaining Lease Payments, 2021" } } }, "localname": "OperatingAndFinanceLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "aimt_OperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": { "order": 10040.0, "parentTag": "aimt_OperatingAndFinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Operating and finance lease liability payments due year two.", "label": "Operating And Finance Lease Liability Payments Due Year Two", "terseLabel": "Remaining Lease Payments, 2020" } } }, "localname": "OperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "aimt_OperatingAndFinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": { "order": 10030.0, "parentTag": "aimt_OperatingAndFinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Operating and finance lease liability payments remainder of fiscal year.", "label": "Operating And Finance Lease Liability Payments Remainder Of Fiscal Year", "terseLabel": "Remaining Lease Payments, 2019" } } }, "localname": "OperatingAndFinanceLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "aimt_OperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails2": { "order": 10010.0, "parentTag": "aimt_OperatingAndFinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Operating and finance lease liability undiscounted excess amount.", "label": "Operating And Finance Lease Liability Undiscounted Excess Amount", "negatedLabel": "Less: Effects of discounting" } } }, "localname": "OperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "aimt_OperatingLeaseObligationsCurrent": { "auth_ref": [], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureAggregateMinimumLeasePaymentsCalculatedUnderASC840Details2": { "order": 10050.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Operating lease obligations current.", "label": "Operating Lease Obligations Current", "negatedLabel": "Less: Operating Lease, current portion" } } }, "localname": "OperatingLeaseObligationsCurrent", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureAggregateMinimumLeasePaymentsCalculatedUnderASC840Details" ], "xbrltype": "monetaryItemType" }, "aimt_OperatingLeaseObligationsNoncurrent": { "auth_ref": [], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureAggregateMinimumLeasePaymentsCalculatedUnderASC840Details2": { "order": 10060.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Operating lease obligations noncurrent.", "label": "Operating Lease Obligations Noncurrent", "terseLabel": "Operating Lease, Long-term lease liabilities" } } }, "localname": "OperatingLeaseObligationsNoncurrent", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureAggregateMinimumLeasePaymentsCalculatedUnderASC840Details" ], "xbrltype": "monetaryItemType" }, "aimt_OtherLoansTriggerAmountToReduceMaturityOfCreditFacility": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Other loans trigger amount to reduce maturity of credit facility.", "label": "Other Loans Trigger Amount To Reduce Maturity Of Credit Facility", "terseLabel": "Other loans trigger amount to reduce 91 days maturity of credit facility" } } }, "localname": "OtherLoansTriggerAmountToReduceMaturityOfCreditFacility", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureLongTermDebtNetOfDiscountsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "aimt_PercentageOfLongTermPurchaseCommitmentMinimumRequiredQuantity": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage of long term purchase commitment minimum required quantity.", "label": "Percentage Of Long Term Purchase Commitment Minimum Required Quantity", "terseLabel": "Percentage of long term purchase commitment minimum required quantity" } } }, "localname": "PercentageOfLongTermPurchaseCommitmentMinimumRequiredQuantity", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "aimt_PercentageOfPrincipalAmountOfLoansPrepaid": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage of principal amount of loans prepaid.", "label": "Percentage Of Principal Amount Of Loans Prepaid", "terseLabel": "Percentage of principal amount of loans prepayment paid on or prior to January 3, 2021" } } }, "localname": "PercentageOfPrincipalAmountOfLoansPrepaid", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureLongTermDebtNetOfDiscountsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "aimt_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Recently adopted accounting pronouncements.", "label": "Recently Adopted Accounting Pronouncements Policy [Text Block]", "terseLabel": "Recently Adopted Accounting Pronouncements" } } }, "localname": "RecentlyAdoptedAccountingPronouncementsPolicyTextBlock", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "aimt_RegulatoryApprovalLastDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Regulatory approval last date.", "label": "Regulatory Approval Last Date", "terseLabel": "Regulatory approval last date" } } }, "localname": "RegulatoryApprovalLastDate", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureLongTermDebtNetOfDiscountsAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "aimt_ScheduleOfOtherInformationRelatedToOperatingAndFinanceLease": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of other information related to operating and finance lease.", "label": "Schedule Of Other Information Related To Operating And Finance Lease", "terseLabel": "Schedule of Other Information Related to Operating Lease" } } }, "localname": "ScheduleOfOtherInformationRelatedToOperatingAndFinanceLease", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "aimt_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfferingPeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share based compensation arrangement by share based payment award offering period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Duration Offering Period", "terseLabel": "ESPP offering period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfferingPeriod", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "aimt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEndingOfPurchasePeriods": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share based compensation arrangement by share based payment award ending of purchase periods.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Ending Of Purchase Periods", "terseLabel": "Description of offering period closing dates" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEndingOfPurchasePeriods", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "aimt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrandDateFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options grand date fair value.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grand Date Fair Value", "terseLabel": "Restricted stock units, aggregate grant date fair value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrandDateFairValue", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "aimt_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContributionAsPercentageOfEligibleCompensation": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share based compensation arrangement by Share based payment award maximum contribution as percentage of eligible compensation.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Maximum Contribution As Percentage Of Eligible Compensation", "terseLabel": "Percentage of maximum contributions employee's eligible compensation" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContributionAsPercentageOfEligibleCompensation", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "aimt_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumPercentageOfVotingRightsOfAllClassesOfStock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share based compensation arrangement by share based payment award minimum percentage of voting rights of all classes of stock.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Minimum Percentage Of Voting Rights Of All Classes Of Stock", "terseLabel": "Minimum percentage of voting rights of all classes of stock" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumPercentageOfVotingRightsOfAllClassesOfStock", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "aimt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedAndSharesVested": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share based compensation arrangement by share based payment award options exercised and shares vested.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercised And Shares Vested", "negatedLabel": "Number of Options, Options exercised and shares vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedAndSharesVested", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "aimt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedAndVestedInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average price of options that were either exercised or vested during the period.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Exercised And Vested In Period Weighted Average Exercise Price", "terseLabel": "Weighted-Average Exercise Price, Options exercised and shares vested" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedAndVestedInPeriodWeightedAverageExercisePrice", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "aimt_ShareBasedCompensationAwardTrancheFourMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share based compensation award tranche four.", "label": "Share Based Compensation Award Tranche Four [Member]", "terseLabel": "Over Four Years" } } }, "localname": "ShareBasedCompensationAwardTrancheFourMember", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "aimt_ShareBasedGoodsAndNonemployeeServicesTransactionStockholdersEquityUnrecognized": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The unrecognized amount by which stockholders' equity will increase by the transaction in which equity securities were issued to pay for goods or nonemployee services.", "label": "Share Based Goods And Nonemployee Services Transaction Stockholders Equity Unrecognized", "terseLabel": "Unrecognized employee stock-based compensation" } } }, "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionStockholdersEquityUnrecognized", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "aimt_ShareBasedGoodsAndNonemployeeServicesTransactionStockholdersEquityUnrecognizedTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average term over which the unrecognized amount that will increase stockholders' equity from the transaction in which equity securities were issued to pay for goods or nonemployee services.", "label": "Share Based Goods And Nonemployee Services Transaction Stockholders Equity Unrecognized Term", "terseLabel": "Expected recognized over weighted-average remaining vesting period" } } }, "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionStockholdersEquityUnrecognizedTerm", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "aimt_ShareBasedGoodsAndNonemployeeServicesTransactionStockholdersEquityVestingPeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Period over which the amount that will increase stockholders' equity from the transaction in which equity securities were issued to pay for goods or nonemployee services will be recognized.", "label": "Share Based Goods And Nonemployee Services Transaction Stockholders Equity Vesting Period", "terseLabel": "Long-term purchase commitment, shares issued, vesting period" } } }, "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionStockholdersEquityVestingPeriod", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "aimt_SignificantAccountingPoliciesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Significant accounting policies.", "label": "Significant Accounting Policies [Line Items]", "terseLabel": "Significant Accounting Policies [Line Items]" } } }, "localname": "SignificantAccountingPoliciesLineItems", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "aimt_SignificantAccountingPoliciesTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Significant accounting policies.", "label": "Significant Accounting Policies [Table]", "terseLabel": "Significant Accounting Policies [Table]" } } }, "localname": "SignificantAccountingPoliciesTable", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "aimt_SignificantAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Significant accounting policy.", "label": "Significant Accounting Policy Policy [Text Block]", "terseLabel": "Significant Accounting Policies" } } }, "localname": "SignificantAccountingPolicyPolicyTextBlock", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "aimt_StockIssuedDuringPeriodFairValueOfSharesIssued": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of restricted common stock issued during the period on the date of issuance.", "label": "Stock Issued During Period Fair Value Of Shares Issued", "terseLabel": "Long-term purchase commitment, fair value" } } }, "localname": "StockIssuedDuringPeriodFairValueOfSharesIssued", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "aimt_StockIssuedDuringPeriodSharesStockOptionsExercisedAndVestingOfRestrictedStockUnits": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock issued during period shares stock options exercised and vesting of restricted stock units.", "label": "Stock Issued During Period Shares Stock Options Exercised And Vesting Of Restricted Stock Units", "terseLabel": "Issuance of common stock upon exercise of vested options and vesting of restricted stock units (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercisedAndVestingOfRestrictedStockUnits", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "sharesItemType" }, "aimt_StockIssuedDuringPeriodSharesUponSecuritiesAgreement": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock issued during period shares upon securities agreement.", "label": "Stock Issued During Period Shares Upon Securities Agreement", "terseLabel": "Issuance of common stock upon securities agreement (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesUponSecuritiesAgreement", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "sharesItemType" }, "aimt_StockIssuedDuringPeriodSharesUponSecuritiesPurchaseAgreement": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock issued during period shares upon securities purchase agreement.", "label": "Stock Issued During Period Shares Upon Securities Purchase Agreement", "terseLabel": "Issuance of common stock upon securities purchase agreement (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesUponSecuritiesPurchaseAgreement", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "sharesItemType" }, "aimt_StockIssuedDuringPeriodValueStockOptionsExercisedAndVestingOfRestrictedStockUnits": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Stock issued during period value stock options exercised and vesting of restricted stock units.", "label": "Stock Issued During Period Value Stock Options Exercised And Vesting Of Restricted Stock Units", "terseLabel": "Issuance of common stock upon exercise of vested options and vesting of restricted stock units" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercisedAndVestingOfRestrictedStockUnits", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "monetaryItemType" }, "aimt_StockIssuedDuringPeriodValueUponSecuritiesAgreement": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Stock issued during period value upon securities agreement.", "label": "Stock Issued During Period Value Upon Securities Agreement", "terseLabel": "Issuance of common stock upon securities agreement" } } }, "localname": "StockIssuedDuringPeriodValueUponSecuritiesAgreement", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "monetaryItemType" }, "aimt_StockIssuedDuringPeriodValueUponSecuritiesPurchaseAgreement": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Stock issued during period value upon securities purchase agreement.", "label": "Stock Issued During Period Value Upon Securities Purchase Agreement", "terseLabel": "Issuance of common stock upon securities purchase agreement" } } }, "localname": "StockIssuedDuringPeriodValueUponSecuritiesPurchaseAgreement", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "monetaryItemType" }, "aimt_TwoThousandFifteenEmployeeStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two thousand fifteen employee stock purchase plan.", "label": "Two Thousand Fifteen Employee Stock Purchase Plan [Member]", "terseLabel": "2015 ESPP" } } }, "localname": "TwoThousandFifteenEmployeeStockPurchasePlanMember", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "aimt_TwoThousandFifteenPlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two thousand fifteen plan.", "label": "Two Thousand Fifteen Plan [Member]", "terseLabel": "2015 Plan" } } }, "localname": "TwoThousandFifteenPlanMember", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationRestrictedStockUnitActivityDetails" ], "xbrltype": "domainItemType" }, "aimt_TwoThousandThirteenPlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two thousand thirteen plan member.", "label": "Two Thousand Thirteen Plan [Member]", "terseLabel": "2013 Plan" } } }, "localname": "TwoThousandThirteenPlanMember", "nsuri": "http://www.aimmune.com/20190630", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "If the value is true, then the document is an amendment to previously-filed/accepted document.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "verboseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Suite No.", "label": "Entity Address Address Line2", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r271" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r271" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r271" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated), (5) Smaller Reporting Accelerated Filer or (6) Smaller Reporting Company and Large Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r271" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r271" ], "lang": { "en-US": { "role": { "documentation": "Indicate if company meets the shell company criteria: a company with no or nominal operations, and with no or nominal assets or assets consisting solely of cash and cash equivalents.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r271" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a smaller reporting company with both a public float and revenues of less than $75 million.", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r271" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "nineDigitItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r38", "r78" ], "lang": { "en-US": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseRecognizedDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Range [Axis]", "terseLabel": "Range" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Range [Member]", "terseLabel": "Range" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Repurchase Agreement Counterparty Name [Domain]", "terseLabel": "Counterparty Name" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseRecognizedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201602Member": { "auth_ref": [ "r205" ], "lang": { "en-US": { "role": { "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).", "label": "Accounting Standards Update201602 [Member]", "terseLabel": "ASU 2016-02" } } }, "localname": "AccountingStandardsUpdate201602Member", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r26" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 10130.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r29" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 10140.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities Current", "terseLabel": "Accrued liabilities", "totalLabel": "Total accrued liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails", "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accrued Liabilities Current [Abstract]" } } }, "localname": "AccruedLiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r5", "r6", "r29" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails": { "order": 10030.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees Current", "terseLabel": "Professional and consulting" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r25", "r112" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails": { "order": 10020.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation Depletion And Amortization Property Plant And Equipment", "negatedLabel": "Less: accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r42", "r43", "r44" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 10070.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income Loss Net Of Tax", "terseLabel": "Accumulated other comprehensive gain(loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r41", "r44", "r45", "r184" ], "lang": { "en-US": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "Accumulated Other Comprehensive Income [Member]", "terseLabel": "Accumulated Other Comprehensive (Loss)/Gain" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r15" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 10060.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid In Capital Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid In Capital [Member]", "terseLabel": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r83" ], "lang": { "en-US": { "role": { "documentation": "Information by new accounting pronouncement.", "label": "Adjustments For New Accounting Pronouncements [Axis]", "terseLabel": "Adjustments for New Accounting Pronouncements" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r137", "r139", "r175", "r176" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.", "label": "Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r139", "r169", "r174" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.", "label": "Allocated Share Based Compensation Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseNetOfEstimatedForfeituresDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r87" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount", "terseLabel": "Antidilutive securities excluded from computation of diluted net loss per share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r87" ], "lang": { "en-US": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r87" ], "lang": { "en-US": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities Name [Domain]", "terseLabel": "Antidilutive Securities, Name" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r99", "r250", "r262" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r2", "r3", "r37" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 10170.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r108" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureAvailableForSaleSecuritiesAndFairValueMeasurementsSummaryOfAggregateMarketValueCostBasisAndGrossUnrealizedGainsAndLossesOfAvailableForSaleInvestmentsBySecurityTypeDetails": { "order": 10010.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax", "terseLabel": "Gross Unrealized Gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureAvailableForSaleSecuritiesAndFairValueMeasurementsSummaryOfAggregateMarketValueCostBasisAndGrossUnrealizedGainsAndLossesOfAvailableForSaleInvestmentsBySecurityTypeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r109" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureAvailableForSaleSecuritiesAndFairValueMeasurementsSummaryOfAggregateMarketValueCostBasisAndGrossUnrealizedGainsAndLossesOfAvailableForSaleInvestmentsBySecurityTypeDetails": { "order": 10020.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax", "negatedLabel": "Gross Unrealized Losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureAvailableForSaleSecuritiesAndFairValueMeasurementsSummaryOfAggregateMarketValueCostBasisAndGrossUnrealizedGainsAndLossesOfAvailableForSaleInvestmentsBySecurityTypeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r106" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureAvailableForSaleSecuritiesAndFairValueMeasurementsSummaryOfAggregateMarketValueCostBasisAndGrossUnrealizedGainsAndLossesOfAvailableForSaleInvestmentsBySecurityTypeDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available For Sale Debt Securities Amortized Cost Basis", "totalLabel": "Amortized Cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureAvailableForSaleSecuritiesAndFairValueMeasurementsSummaryOfAggregateMarketValueCostBasisAndGrossUnrealizedGainsAndLossesOfAvailableForSaleInvestmentsBySecurityTypeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r102", "r107" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureAvailableForSaleSecuritiesAndFairValueMeasurementsSummaryOfAggregateMarketValueCostBasisAndGrossUnrealizedGainsAndLossesOfAvailableForSaleInvestmentsBySecurityTypeDetails": { "order": 10030.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available For Sale Securities Debt Securities", "terseLabel": "Total investments" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureAvailableForSaleSecuritiesAndFairValueMeasurementsSummaryOfAggregateMarketValueCostBasisAndGrossUnrealizedGainsAndLossesOfAvailableForSaleInvestmentsBySecurityTypeDetails", "http://www.aimmune.com/20190630/taxonomy/role/DisclosureAvailableForSaleSecuritiesAndFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "auth_ref": [ "r104" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 10230.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.", "label": "Available For Sale Securities Debt Securities Current", "terseLabel": "Short-term investments" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r140", "r171" ], "lang": { "en-US": { "role": { "documentation": "Information by award type pertaining to equity-based compensation.", "label": "Award Type [Axis]", "terseLabel": "Award Type" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationRestrictedStockUnitActivityDetails", "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseRecognizedDetails", "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfUnrecognizedStockBasedCompensationExpenseAndExpectedPeriodDetails", "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetRelatedDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Balance Sheet Related Disclosures [Abstract]" } } }, "localname": "BalanceSheetRelatedDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_BaseRateMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Minimum rate investor will accept.", "label": "Base Rate [Member]", "terseLabel": "Alternate Base Rate" } } }, "localname": "BaseRateMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureLongTermDebtNetOfDiscountsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis Of Accounting Policy Policy [Text Block]", "terseLabel": "Basis of Preparation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BuildingMember": { "auth_ref": [ "r111" ], "lang": { "en-US": { "role": { "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.", "label": "Building [Member]", "terseLabel": "Buildings" } } }, "localname": "BuildingMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r0", "r82", "r97" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Business Description And Basis Of Presentation [Text Block]", "terseLabel": "Formation and Business of the Company" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureFormationAndBusinessOfCompany" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r71", "r72", "r73" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred But Not Yet Paid", "terseLabel": "Property and equipment purchases included in accounts payable and accrued liabilities" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalLeaseObligationsCurrent": { "auth_ref": [ "r11", "r203", "r204" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureAggregateMinimumLeasePaymentsCalculatedUnderASC840Details2": { "order": 10030.0, "parentTag": "us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of capital lease obligation due within one year or the normal operating cycle, if longer.", "label": "Capital Lease Obligations Current", "negatedLabel": "Less: Financing Lease, current portion" } } }, "localname": "CapitalLeaseObligationsCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureAggregateMinimumLeasePaymentsCalculatedUnderASC840Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalLeaseObligationsNoncurrent": { "auth_ref": [ "r32", "r203", "r204" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureAggregateMinimumLeasePaymentsCalculatedUnderASC840Details2": { "order": 10040.0, "parentTag": "us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal, through the balance sheet date and due to be paid more than one year (or one operating cycle, if longer) after the balance sheet date.", "label": "Capital Lease Obligations Noncurrent", "terseLabel": "Financing Lease, Long-term lease liabilities" } } }, "localname": "CapitalLeaseObligationsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureAggregateMinimumLeasePaymentsCalculatedUnderASC840Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalLeasesFutureMinimumPaymentsDue": { "auth_ref": [ "r204" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureAggregateMinimumLeasePaymentsCalculatedUnderASC840Details": { "order": 10090.0, "parentTag": "us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of minimum lease payments for capital leases.", "label": "Capital Leases Future Minimum Payments Due", "totalLabel": "Total financing lease payments" } } }, "localname": "CapitalLeasesFutureMinimumPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureAggregateMinimumLeasePaymentsCalculatedUnderASC840Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears": { "auth_ref": [ "r204" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureAggregateMinimumLeasePaymentsCalculatedUnderASC840Details": { "order": 10150.0, "parentTag": "us-gaap_CapitalLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of minimum lease payments for capital leases due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Capital Leases Future Minimum Payments Due In Five Years", "terseLabel": "Financing Lease, 2023" } } }, "localname": "CapitalLeasesFutureMinimumPaymentsDueInFiveYears", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureAggregateMinimumLeasePaymentsCalculatedUnderASC840Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears": { "auth_ref": [ "r204" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureAggregateMinimumLeasePaymentsCalculatedUnderASC840Details": { "order": 10140.0, "parentTag": "us-gaap_CapitalLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of minimum lease payments for capital leases due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Capital Leases Future Minimum Payments Due In Four Years", "terseLabel": "Financing Lease, 2022" } } }, "localname": "CapitalLeasesFutureMinimumPaymentsDueInFourYears", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureAggregateMinimumLeasePaymentsCalculatedUnderASC840Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears": { "auth_ref": [ "r204" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureAggregateMinimumLeasePaymentsCalculatedUnderASC840Details": { "order": 10130.0, "parentTag": "us-gaap_CapitalLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of minimum lease payments for capital leases due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Capital Leases Future Minimum Payments Due In Three Years", "terseLabel": "Financing Lease, 2021" } } }, "localname": "CapitalLeasesFutureMinimumPaymentsDueInThreeYears", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureAggregateMinimumLeasePaymentsCalculatedUnderASC840Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears": { "auth_ref": [ "r204" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureAggregateMinimumLeasePaymentsCalculatedUnderASC840Details": { "order": 10120.0, "parentTag": "us-gaap_CapitalLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of minimum lease payments for capital leases due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Capital Leases Future Minimum Payments Due In Two Years", "terseLabel": "Financing Lease, 2020" } } }, "localname": "CapitalLeasesFutureMinimumPaymentsDueInTwoYears", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureAggregateMinimumLeasePaymentsCalculatedUnderASC840Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter": { "auth_ref": [ "r204" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureAggregateMinimumLeasePaymentsCalculatedUnderASC840Details": { "order": 10160.0, "parentTag": "us-gaap_CapitalLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of minimum lease payments for capital leases due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Capital Leases Future Minimum Payments Due Thereafter", "terseLabel": "Financing Lease, 2020, Thereafter" } } }, "localname": "CapitalLeasesFutureMinimumPaymentsDueThereafter", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureAggregateMinimumLeasePaymentsCalculatedUnderASC840Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments": { "auth_ref": [ "r204" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureAggregateMinimumLeasePaymentsCalculatedUnderASC840Details": { "order": 10100.0, "parentTag": "us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount necessary to reduce net minimum lease payments to present value for capital leases.", "label": "Capital Leases Future Minimum Payments Interest Included In Payments", "negatedLabel": "Less: Financing Lease, amount representing interest" } } }, "localname": "CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureAggregateMinimumLeasePaymentsCalculatedUnderASC840Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments": { "auth_ref": [ "r204" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureAggregateMinimumLeasePaymentsCalculatedUnderASC840Details": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureAggregateMinimumLeasePaymentsCalculatedUnderASC840Details2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of minimum lease payments for capital leases net of executory costs, including amounts paid by the lessee to the lessor for insurance, maintenance and taxes.", "label": "Capital Leases Future Minimum Payments Present Value Of Net Minimum Payments", "totalLabel": "Financing Lease Value of lease liabilities under ASC 840" } } }, "localname": "CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureAggregateMinimumLeasePaymentsCalculatedUnderASC840Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear": { "auth_ref": [], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureAggregateMinimumLeasePaymentsCalculatedUnderASC840Details": { "order": 10110.0, "parentTag": "us-gaap_CapitalLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of minimum lease payments for capital leases due in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Capital Leases Future Minimum Payments Remainder Of Fiscal Year", "terseLabel": "Financing Lease, 2019" } } }, "localname": "CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureAggregateMinimumLeasePaymentsCalculatedUnderASC840Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Cash And Cash Equivalents [Abstract]", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureAvailableForSaleSecuritiesAndFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r1", "r22", "r70" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 10220.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash And Cash Equivalents At Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash And Cash Equivalents Fair Value Disclosure", "terseLabel": "Total cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureAvailableForSaleSecuritiesAndFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsAndShortTermInvestments": { "auth_ref": [ "r22" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.", "label": "Cash Cash Equivalents And Short Term Investments", "terseLabel": "Cash, cash equivalents and investments" } } }, "localname": "CashCashEquivalentsAndShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r65", "r70", "r74" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations", "periodEndLabel": "Cash and cash equivalents at the end of the period", "periodStartLabel": "Cash and cash equivalents at the beginning of the period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r65", "r196" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect", "totalLabel": "Net increase (decrease) in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract]", "terseLabel": "Supplemental disclosure of non-cash investing and financing activities:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r118" ], "lang": { "en-US": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial Paper" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureAvailableForSaleSecuritiesAndFairValueMeasurementsSummaryOfAggregateMarketValueCostBasisAndGrossUnrealizedGainsAndLossesOfAvailableForSaleInvestmentsBySecurityTypeDetails", "http://www.aimmune.com/20190630/taxonomy/role/DisclosureAvailableForSaleSecuritiesAndFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r34", "r116", "r255", "r266" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 10020.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments And Contingencies", "terseLabel": "Commitments and contingencies (Note 6)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Commitments And Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r115", "r117" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments And Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r35" ], "lang": { "en-US": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock Capital Shares Reserved For Future Issuance", "terseLabel": "Common stock, shares reserved for issuance" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseRecognizedDetails", "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock Par Or Stated Value Per Share", "terseLabel": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock Shares Issued", "terseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r14", "r124" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock Shares Outstanding", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r14" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 10050.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock Value", "terseLabel": "Common stock, par value $0.0001 per share\u2014290,000 shares authorized as of June 30, 2019, and December 31, 2018; 62,660 and 62,142 shares issued and outstanding as of June 30, 2019, and December 31, 2018, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r47", "r49", "r50" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income Net Of Tax", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]", "terseLabel": "Computer Equipment" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r75", "r181", "r187", "r188" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation Policy [Text Block]", "terseLabel": "Basis of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction In Progress [Member]", "terseLabel": "Construction in Progress" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractualObligation": { "auth_ref": [], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureAggregateMinimumLeasePaymentsCalculatedUnderASC840Details": { "order": 10010.0, "parentTag": "aimt_ContractualObligationPresentValueOfNetMinimumPayments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.", "label": "Contractual Obligation", "totalLabel": "Total lease payments" } } }, "localname": "ContractualObligation", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureAggregateMinimumLeasePaymentsCalculatedUnderASC840Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractualObligationDueAfterFifthYear": { "auth_ref": [], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureAggregateMinimumLeasePaymentsCalculatedUnderASC840Details": { "order": 10080.0, "parentTag": "us-gaap_ContractualObligation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of contractual obligation due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Contractual Obligation Due After Fifth Year", "terseLabel": "Remaining Lease Payments, Thereafter" } } }, "localname": "ContractualObligationDueAfterFifthYear", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureAggregateMinimumLeasePaymentsCalculatedUnderASC840Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractualObligationDueInFifthYear": { "auth_ref": [], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureAggregateMinimumLeasePaymentsCalculatedUnderASC840Details": { "order": 10070.0, "parentTag": "us-gaap_ContractualObligation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of contractual obligation due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Contractual Obligation Due In Fifth Year", "terseLabel": "Remaining Lease Payments, 2023" } } }, "localname": "ContractualObligationDueInFifthYear", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureAggregateMinimumLeasePaymentsCalculatedUnderASC840Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractualObligationDueInFourthYear": { "auth_ref": [], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureAggregateMinimumLeasePaymentsCalculatedUnderASC840Details": { "order": 10060.0, "parentTag": "us-gaap_ContractualObligation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of contractual obligation due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Contractual Obligation Due In Fourth Year", "terseLabel": "Remaining Lease Payments, 2022" } } }, "localname": "ContractualObligationDueInFourthYear", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureAggregateMinimumLeasePaymentsCalculatedUnderASC840Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractualObligationDueInSecondYear": { "auth_ref": [], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureAggregateMinimumLeasePaymentsCalculatedUnderASC840Details": { "order": 10040.0, "parentTag": "us-gaap_ContractualObligation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of contractual obligation due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Contractual Obligation Due In Second Year", "terseLabel": "Remaining Lease Payments, 2020" } } }, "localname": "ContractualObligationDueInSecondYear", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureAggregateMinimumLeasePaymentsCalculatedUnderASC840Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractualObligationDueInThirdYear": { "auth_ref": [], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureAggregateMinimumLeasePaymentsCalculatedUnderASC840Details": { "order": 10050.0, "parentTag": "us-gaap_ContractualObligation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of contractual obligation due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Contractual Obligation Due In Third Year", "terseLabel": "Remaining Lease Payments, 2021" } } }, "localname": "ContractualObligationDueInThirdYear", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureAggregateMinimumLeasePaymentsCalculatedUnderASC840Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractualObligationFiscalYearMaturityScheduleTableTextBlock": { "auth_ref": [ "r272" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the aggregate amount of payments due on known contractual obligations for the five years following the date of the latest balance sheet and the combined aggregate amount of maturities of known contractual obligations.", "label": "Contractual Obligation Fiscal Year Maturity Schedule Table [Text Block]", "terseLabel": "Schedule of Future Aggregate Minimum Lease Payments Calculated under ASC 840" } } }, "localname": "ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear": { "auth_ref": [], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureAggregateMinimumLeasePaymentsCalculatedUnderASC840Details": { "order": 10030.0, "parentTag": "us-gaap_ContractualObligation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of contractual obligation maturing in the remainder of the fiscal year following the latest fiscal year ended.", "label": "Contractual Obligation Future Minimum Payments Due Remainder Of Fiscal Year", "terseLabel": "Remaining Lease Payments, 2019" } } }, "localname": "ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureAggregateMinimumLeasePaymentsCalculatedUnderASC840Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r132", "r135" ], "lang": { "en-US": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate Debt Securities" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureAvailableForSaleSecuritiesAndFairValueMeasurementsSummaryOfAggregateMarketValueCostBasisAndGrossUnrealizedGainsAndLossesOfAvailableForSaleInvestmentsBySecurityTypeDetails", "http://www.aimmune.com/20190630/taxonomy/role/DisclosureAvailableForSaleSecuritiesAndFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1": { "auth_ref": [ "r85" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the cumulative effect on retained earnings net of related income tax effect.", "label": "Cumulative Effect On Retained Earnings Net Of Tax1", "terseLabel": "Accumulated depreciation upon adoption of ASU Topic 842" } } }, "localname": "CumulativeEffectOnRetainedEarningsNetOfTax1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r123" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Long-Term Debt, Net of Discounts" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureLongTermDebtNetOfDiscounts" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument Basis Spread On Variable Rate1", "terseLabel": "Loan, spread on variable rate" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureLongTermDebtNetOfDiscountsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r12", "r120", "r251", "r260" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureLongTermDebtNetOfDiscountsScheduleOfFuturePrincipalPaymentsOfLongTermDebtDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.aimmune.com/20190630/taxonomy/role/DisclosureLongTermDebtNetOfDiscountsScheduleOfShortTermAndLongTermDebtObligationsDetails": { "order": 10040.0, "parentTag": "aimt_DebtInstrumentCarryingAmountNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Debt Instrument Carrying Amount", "terseLabel": "Long term debt, outstanding", "totalLabel": "Total", "verboseLabel": "Principal amount of long-term debt" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureLongTermDebtNetOfDiscountsAdditionalInformationDetails", "http://www.aimmune.com/20190630/taxonomy/role/DisclosureLongTermDebtNetOfDiscountsScheduleOfFuturePrincipalPaymentsOfLongTermDebtDetails", "http://www.aimmune.com/20190630/taxonomy/role/DisclosureLongTermDebtNetOfDiscountsScheduleOfShortTermAndLongTermDebtObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r31", "r122", "r198" ], "lang": { "en-US": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt Instrument Interest Rate Effective Percentage", "terseLabel": "Debt instrument, interest rate" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureLongTermDebtNetOfDiscountsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureLongTermDebtNetOfDiscountsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentRedemptionPricePercentage": { "auth_ref": [ "r258" ], "lang": { "en-US": { "role": { "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.", "label": "Debt Instrument Redemption Price Percentage", "terseLabel": "Loan redemption price, percentage" } } }, "localname": "DebtInstrumentRedemptionPricePercentage", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureLongTermDebtNetOfDiscountsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r32", "r79", "r125", "r126", "r127", "r128", "r197", "r198", "r200", "r259" ], "lang": { "en-US": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Debt Instrument [Table]", "terseLabel": "Debt Instrument [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureLongTermDebtNetOfDiscountsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "auth_ref": [ "r121", "r199" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureLongTermDebtNetOfDiscountsScheduleOfShortTermAndLongTermDebtObligationsDetails": { "order": 10020.0, "parentTag": "us-gaap_LongTermDebtNoncurrent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.", "label": "Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net", "negatedLabel": "Unamortized discount relating to deferred financing costs, net" } } }, "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureLongTermDebtNetOfDiscountsScheduleOfShortTermAndLongTermDebtObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r68", "r110" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 10130.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r131", "r177" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.", "label": "Disclosure Of Compensation Related Costs Share Based Payments [Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": { "auth_ref": [ "r80", "r224", "r254", "r267" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.", "label": "Due To Related Parties Current And Noncurrent", "terseLabel": "Accrued liabilities due" } } }, "localname": "DueToRelatedPartiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureRelatedPartyTransactionAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r86" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share Basic And Diluted", "terseLabel": "Net loss per common share, basic and diluted" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSUnaudited" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r89" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Loss per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureNetLossPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r29" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails": { "order": 10010.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee Related Liabilities Current", "terseLabel": "Compensation and benefits" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]", "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseNetOfEstimatedForfeituresDetails", "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseRecognizedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r170" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Unrecognized cost of unvested share-based compensation awards.", "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized", "terseLabel": "Unrecognized stock compensation expense" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfUnrecognizedStockBasedCompensationExpenseAndExpectedPeriodDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized [Abstract]" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r170" ], "lang": { "en-US": { "role": { "documentation": "Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1", "terseLabel": "Weighted-average remaining vesting period (years)" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfUnrecognizedStockBasedCompensationExpenseAndExpectedPeriodDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "auth_ref": [ "r170" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Unrecognized cost of unvested share-based awards, other than options, awarded to employees as compensation.", "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options", "terseLabel": "Recognized stock-based compensation expense", "verboseLabel": "Unrecognized stock compensation expense" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfUnrecognizedStockBasedCompensationExpenseAndExpectedPeriodDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r170" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Unrecognized cost of unvested options awarded to employees as compensation.", "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options", "terseLabel": "Unrecognized stock compensation expense" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfUnrecognizedStockBasedCompensationExpenseAndExpectedPeriodDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.", "label": "Employee Stock [Member]", "terseLabel": "Employee Stock Purchase Plan" } } }, "localname": "EmployeeStockMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfWeightedAverageAssumptionsToFairValueOfStockOptionsDetails", "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "An arrangement whereby an employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Although there are variations, normally, after vesting, when an option is exercised, the employee-holder pays the strike value in cash to the issuing employer-entity and receives equity shares. The equity shares can be sold into the market for cash at the current market price without restriction. Options may be used to attract, retain and incentivize employees, in addition to their regular salary and other benefits.", "label": "Employee Stock Option [Member]", "terseLabel": "Stock Options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails", "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfUnrecognizedStockBasedCompensationExpenseAndExpectedPeriodDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquipmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tangible personal property used to produce goods and services.", "label": "Equipment [Member]", "terseLabel": "Manufacturing Equipment" } } }, "localname": "EquipmentMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r124" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseRecognizedDetails", "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount": { "auth_ref": [ "r192" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.", "label": "Fair Value Assets Level1 To Level2 Transfers Amount", "terseLabel": "Fair value assets transfers between level 1 to level 2" } } }, "localname": "FairValueAssetsLevel1ToLevel2TransfersAmount", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureAvailableForSaleSecuritiesAndFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount": { "auth_ref": [ "r192" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.", "label": "Fair Value Assets Level2 To Level1 Transfers Amount", "terseLabel": "Fair value assets transfers between level 2 to level 1" } } }, "localname": "FairValueAssetsLevel2ToLevel1TransfersAmount", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureAvailableForSaleSecuritiesAndFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]", "terseLabel": "Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]" } } }, "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureAvailableForSaleSecuritiesAndFairValueMeasurementsSummaryOfAggregateMarketValueCostBasisAndGrossUnrealizedGainsAndLossesOfAvailableForSaleInvestmentsBySecurityTypeDetails", "http://www.aimmune.com/20190630/taxonomy/role/DisclosureAvailableForSaleSecuritiesAndFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "auth_ref": [ "r190", "r194", "r195" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value By Balance Sheet Grouping [Table]", "terseLabel": "Fair Value By Balance Sheet Grouping [Table]" } } }, "localname": "FairValueByBalanceSheetGroupingTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureAvailableForSaleSecuritiesAndFairValueMeasurementsSummaryOfAggregateMarketValueCostBasisAndGrossUnrealizedGainsAndLossesOfAvailableForSaleInvestmentsBySecurityTypeDetails", "http://www.aimmune.com/20190630/taxonomy/role/DisclosureAvailableForSaleSecuritiesAndFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTextBlock": { "auth_ref": [ "r190", "r194" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value By Balance Sheet Grouping [Text Block]", "terseLabel": "Summary of Financial Instruments Measured at Fair Value on a Recurring Basis" } } }, "localname": "FairValueByBalanceSheetGroupingTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureAvailableForSaleSecuritiesAndFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r132", "r133", "r135", "r191", "r231" ], "lang": { "en-US": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value By Fair Value Hierarchy Level [Axis]", "terseLabel": "Level 2" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureAvailableForSaleSecuritiesAndFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r189" ], "lang": { "en-US": { "role": { "documentation": "Information by measurement frequency.", "label": "Fair Value By Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureAvailableForSaleSecuritiesAndFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r132", "r133", "r135", "r191", "r232" ], "lang": { "en-US": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value Inputs Level1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureAvailableForSaleSecuritiesAndFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r132", "r133", "r135", "r191", "r233" ], "lang": { "en-US": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value Inputs Level2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureAvailableForSaleSecuritiesAndFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r132", "r133", "r135", "r191", "r234" ], "lang": { "en-US": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value Inputs Level3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureAvailableForSaleSecuritiesAndFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [ "r189", "r193" ], "lang": { "en-US": { "role": { "documentation": "Provides the general categories used to describe the frequency with which financial assets and liabilities (as defined) are measured at fair value (on a recurring or nonrecurring basis).", "label": "Fair Value Measurement Frequency [Domain]", "terseLabel": "Fair Value, Measurement Frequency" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureAvailableForSaleSecuritiesAndFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement Policy Policy [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Measurements Fair Value Hierarchy [Domain]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureAvailableForSaleSecuritiesAndFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r189", "r193" ], "lang": { "en-US": { "role": { "documentation": "This item represents a description of the frequency with which certain items are measured at fair value. Items measured at fair value on a recurring basis generally include those items for which measurement inputs are readily available and which are measured at fair value at successive reporting periods.", "label": "Fair Value Measurements Recurring [Member]", "terseLabel": "Fair Value Measurements Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureAvailableForSaleSecuritiesAndFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinanceLeaseCostAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Finance Lease Cost [Abstract]", "terseLabel": "Finance lease cost" } } }, "localname": "FinanceLeaseCostAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesComponentOfLeaseCostsIncludedInCondensedConsolidatedStatementsOfIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinanceLeaseInterestExpense": { "auth_ref": [ "r208", "r215", "r222" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesComponentOfLeaseCostsIncludedInCondensedConsolidatedStatementsOfIncomeDetails": { "order": 10030.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of interest expense on finance lease liability.", "label": "Finance Lease Interest Expense", "terseLabel": "Interest on lease liabilities" } } }, "localname": "FinanceLeaseInterestExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesComponentOfLeaseCostsIncludedInCondensedConsolidatedStatementsOfIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiability": { "auth_ref": [ "r207", "r221" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails2": { "order": 10040.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.", "label": "Finance Lease Liability", "totalLabel": "Financing lease, Present value of lease liabilities" } } }, "localname": "FinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityCurrent": { "auth_ref": [ "r207" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": { "order": 10090.0, "parentTag": "us-gaap_FinanceLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.", "label": "Finance Lease Liability Current", "negatedLabel": "Less: Financing lease, current portion" } } }, "localname": "FinanceLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "auth_ref": [ "r207" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": { "order": 10100.0, "parentTag": "us-gaap_FinanceLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.", "label": "Finance Lease Liability Noncurrent", "terseLabel": "Financing lease, Long-term lease liabilities" } } }, "localname": "FinanceLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "auth_ref": [ "r221" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.", "label": "Finance Lease Liability Payments Due", "totalLabel": "Financing lease, Total lease payments" } } }, "localname": "FinanceLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r221" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": { "order": 10160.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due after fifth fiscal year following latest fiscal year.", "label": "Finance Lease Liability Payments Due After Year Five", "terseLabel": "Financing lease, Thereafter" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r221" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": { "order": 10150.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in fifth fiscal year following latest fiscal year.", "label": "Finance Lease Liability Payments Due Year Five", "terseLabel": "Financing lease, 2023" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r221" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": { "order": 10140.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in fourth fiscal year following latest fiscal year.", "label": "Finance Lease Liability Payments Due Year Four", "terseLabel": "Financing lease, 2022" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r221" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": { "order": 10130.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in third fiscal year following latest fiscal year.", "label": "Finance Lease Liability Payments Due Year Three", "terseLabel": "Financing lease, 2021" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r221" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": { "order": 10120.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in second fiscal year following latest fiscal year.", "label": "Finance Lease Liability Payments Due Year Two", "terseLabel": "Financing lease, 2020" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r221" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": { "order": 10110.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in remainder of fiscal year following latest fiscal year ended.", "label": "Finance Lease Liability Payments Remainder Of Fiscal Year", "terseLabel": "Financing lease, 2019" } } }, "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r221" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails2": { "order": 10030.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.", "label": "Finance Lease Liability Undiscounted Excess Amount", "negatedLabel": "Less: Financing lease, Effects of discounting" } } }, "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeasePrincipalPayments": { "auth_ref": [ "r209", "r217" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow for principal payment on finance lease.", "label": "Finance Lease Principal Payments", "terseLabel": "Operating cash flows from finance leases" } } }, "localname": "FinanceLeasePrincipalPayments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOtherInformationRelatedToOperatingLeaseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "auth_ref": [ "r208", "r215", "r222" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesComponentOfLeaseCostsIncludedInCondensedConsolidatedStatementsOfIncomeDetails": { "order": 10020.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.", "label": "Finance Lease Right Of Use Asset Amortization", "terseLabel": "Amortization of leased assets" } } }, "localname": "FinanceLeaseRightOfUseAssetAmortization", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesComponentOfLeaseCostsIncludedInCondensedConsolidatedStatementsOfIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r219", "r222" ], "lang": { "en-US": { "role": { "documentation": "Weighted average discount rate for finance lease calculated at point in time.", "label": "Finance Lease Weighted Average Discount Rate Percent", "terseLabel": "Financing lease, Weighted-average incremental borrowing rate" } } }, "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r218", "r222" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Finance Lease Weighted Average Remaining Lease Term1", "verboseLabel": "Financing lease, Weighted-average remaining lease term" } } }, "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureAvailableForSaleSecuritiesAndFairValueMeasurementsSummaryOfAggregateMarketValueCostBasisAndGrossUnrealizedGainsAndLossesOfAvailableForSaleInvestmentsBySecurityTypeDetails", "http://www.aimmune.com/20190630/taxonomy/role/DisclosureAvailableForSaleSecuritiesAndFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture And Fixtures [Member]", "terseLabel": "Furniture and Equipment" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r54" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSUnaudited": { "order": 10090.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General And Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r53" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General And Administrative Expense [Member]", "terseLabel": "General and Administrative" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseNetOfEstimatedForfeituresDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOfInvestments": { "auth_ref": [ "r105" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount by which the fair value of an investment is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.", "label": "Impairment Of Investments", "terseLabel": "Other than temporary impairment losses" } } }, "localname": "ImpairmentOfInvestments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureAvailableForSaleSecuritiesAndFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r51", "r84", "r248", "r256", "r269" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSUnaudited": { "order": 10030.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest", "totalLabel": "Loss before provision for income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r114" ], "lang": { "en-US": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseNetOfEstimatedForfeituresDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseNetOfEstimatedForfeituresDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r76", "r98", "r179" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSUnaudited": { "order": 10040.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense Benefit", "terseLabel": "Provision for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r67" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 10180.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase Decrease In Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r67" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 10190.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase Decrease In Accrued Liabilities", "terseLabel": "Accrued liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Increase Decrease In Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "auth_ref": [ "r67" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 10200.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in operating liabilities classified as other.", "label": "Increase Decrease In Other Operating Liabilities", "terseLabel": "Other liabilities" } } }, "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r67" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 10170.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase Decrease In Prepaid Deferred Expense And Other Assets", "negatedLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "auth_ref": [], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSUnaudited": { "order": 10060.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net amount of nonoperating interest income (expense).", "label": "Interest Income Expense Nonoperating Net", "terseLabel": "Interest income, net" } } }, "localname": "InterestIncomeExpenseNonoperatingNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": { "auth_ref": [ "r55" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 10160.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.", "label": "Investment Income Net Amortization Of Discount And Premium", "negatedLabel": "Amortization of premium on investment securities" } } }, "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Investments [Abstract]", "terseLabel": "Investments:" } } }, "localname": "InvestmentsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureAvailableForSaleSecuritiesAndFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r220", "r222" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesComponentOfLeaseCostsIncludedInCondensedConsolidatedStatementsOfIncomeDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease Cost", "totalLabel": "Net lease cost" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesComponentOfLeaseCostsIncludedInCondensedConsolidatedStatementsOfIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Lease Cost [Abstract]", "terseLabel": "Lease Cost" } } }, "localname": "LeaseCostAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesComponentOfLeaseCostsIncludedInCondensedConsolidatedStatementsOfIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r220" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease Cost Table [Text Block]", "terseLabel": "Component of Lease Costs Included in Condensed Consolidated Statements of Income" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r111" ], "lang": { "en-US": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LesseeFinanceLeaseDescription": { "auth_ref": [ "r211" ], "lang": { "en-US": { "role": { "documentation": "Description of lessee's finance lease.", "label": "Lessee Finance Lease Description", "terseLabel": "Finance Lease, Description" } } }, "localname": "LesseeFinanceLeaseDescription", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeFinanceLeaseExistenceOfOptionToExtend": { "auth_ref": [ "r213" ], "lang": { "en-US": { "role": { "documentation": "Indicates (true false) whether lessee has option to extend finance lease.", "label": "Lessee Finance Lease Existence Of Option To Extend", "terseLabel": "Finance lease, existence of option to extend" } } }, "localname": "LesseeFinanceLeaseExistenceOfOptionToExtend", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "booleanItemType" }, "us-gaap_LesseeFinanceLeaseOptionToExtend": { "auth_ref": [ "r213" ], "lang": { "en-US": { "role": { "documentation": "Description of terms and conditions of option to extend lessee's finance lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.", "label": "Lessee Finance Lease Option To Extend", "terseLabel": "Finance lease, option to extend" } } }, "localname": "LesseeFinanceLeaseOptionToExtend", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeFinanceLeaseVariableLeasePaymentTermsAndConditions": { "auth_ref": [ "r212" ], "lang": { "en-US": { "role": { "documentation": "Description of basis, terms, and conditions on which variable lease payment for lessee's finance lease is determined.", "label": "Lessee Finance Lease Variable Lease Payment Terms And Conditions", "terseLabel": "Finance lease, variable lease payment, terms and conditions" } } }, "localname": "LesseeFinanceLeaseVariableLeasePaymentTermsAndConditions", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseDescription": { "auth_ref": [ "r211" ], "lang": { "en-US": { "role": { "documentation": "Description of lessee's operating lease.", "label": "Lessee Operating Lease Description", "terseLabel": "Operating lease, description" } } }, "localname": "LesseeOperatingLeaseDescription", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": { "auth_ref": [ "r213" ], "lang": { "en-US": { "role": { "documentation": "Indicates (true false) whether lessee has option to extend operating lease.", "label": "Lessee Operating Lease Existence Of Option To Extend", "terseLabel": "Operating lease, existence of option to extend" } } }, "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "booleanItemType" }, "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedDescription": { "auth_ref": [ "r214" ], "lang": { "en-US": { "role": { "documentation": "Description of lessee's operating lease that has not yet commenced. Including, but not limited to, nature of involvement with construction or design of underlying asset for lease.", "label": "Lessee Operating Lease Lease Not Yet Commenced Description", "terseLabel": "Additional operating leases, not yet commenced, description" } } }, "localname": "LesseeOperatingLeaseLeaseNotYetCommencedDescription", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1": { "auth_ref": [ "r214" ], "lang": { "en-US": { "role": { "documentation": "Term of lessee's operating lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee Operating Lease Lease Not Yet Commenced Term Of Contract1", "terseLabel": "Additional operating leases, not yet commenced, term" } } }, "localname": "LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r221" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.", "label": "Lessee Operating Lease Liability Payments Due", "totalLabel": "Operating Lease, Total lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r221" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": { "order": 10240.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.", "label": "Lessee Operating Lease Liability Payments Due After Year Five", "terseLabel": "Operating lease, Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r221" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": { "order": 10230.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.", "label": "Lessee Operating Lease Liability Payments Due Year Five", "terseLabel": "Operating lease, 2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r221" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": { "order": 10220.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.", "label": "Lessee Operating Lease Liability Payments Due Year Four", "terseLabel": "Operating lease, 2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r221" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": { "order": 10210.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.", "label": "Lessee Operating Lease Liability Payments Due Year Three", "terseLabel": "Operating lease, 2021" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r221" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": { "order": 10200.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.", "label": "Lessee Operating Lease Liability Payments Due Year Two", "terseLabel": "Operating lease, 2020" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r221" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": { "order": 10190.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.", "label": "Lessee Operating Lease Liability Payments Remainder Of Fiscal Year", "terseLabel": "Operating lease, 2019" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r221" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails2": { "order": 10050.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee Operating Lease Liability Undiscounted Excess Amount", "negatedLabel": "Less: Operating lease, Effects of discounting" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseOptionToExtend": { "auth_ref": [ "r213" ], "lang": { "en-US": { "role": { "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.", "label": "Lessee Operating Lease Option To Extend", "terseLabel": "Operating lease, option to extend" } } }, "localname": "LesseeOperatingLeaseOptionToExtend", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseVariableLeasePaymentTermsAndConditions": { "auth_ref": [ "r212" ], "lang": { "en-US": { "role": { "documentation": "Description of basis, terms, and conditions on which variable lease payment for lessee's operating lease is determined.", "label": "Lessee Operating Lease Variable Lease Payment Terms And Conditions", "terseLabel": "Operating lease, variable lease payment, terms and conditions" } } }, "localname": "LesseeOperatingLeaseVariableLeasePaymentTermsAndConditions", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r28" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 10010.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r19", "r252", "r264" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities And Stockholders Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities And Stockholders Equity [Abstract]", "terseLabel": "Liabilities and Stockholders\u2019 Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r30" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 10090.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityAxis": { "auth_ref": [ "r27", "r79" ], "lang": { "en-US": { "role": { "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.", "label": "Line Of Credit Facility [Axis]", "terseLabel": "Lender Name" } } }, "localname": "LineOfCreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureLongTermDebtNetOfDiscountsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityExpirationDate1": { "auth_ref": [ "r27" ], "lang": { "en-US": { "role": { "documentation": "Date the credit facility terminates, in CCYY-MM-DD format.", "label": "Line Of Credit Facility Expiration Date1", "terseLabel": "Line of credit facility maturity date" } } }, "localname": "LineOfCreditFacilityExpirationDate1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureLongTermDebtNetOfDiscountsAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "us-gaap_LineOfCreditFacilityInterestRateDuringPeriod": { "auth_ref": [ "r27" ], "lang": { "en-US": { "role": { "documentation": "The effective interest rate during the reporting period.", "label": "Line Of Credit Facility Interest Rate During Period", "terseLabel": "Line of credit facility, interest rate" } } }, "localname": "LineOfCreditFacilityInterestRateDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureLongTermDebtNetOfDiscountsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LineOfCreditFacilityLenderDomain": { "auth_ref": [ "r27" ], "lang": { "en-US": { "role": { "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.", "label": "Line Of Credit Facility Lender [Domain]", "terseLabel": "Line of Credit Facility, Lender" } } }, "localname": "LineOfCreditFacilityLenderDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureLongTermDebtNetOfDiscountsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r27" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line Of Credit Facility Maximum Borrowing Capacity", "terseLabel": "Loan agreement, maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureLongTermDebtNetOfDiscountsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": { "auth_ref": [ "r27" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).", "label": "Line Of Credit Facility Remaining Borrowing Capacity", "terseLabel": "Loan agreement, remaining borrowing capacity upon certain conditions" } } }, "localname": "LineOfCreditFacilityRemainingBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureLongTermDebtNetOfDiscountsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LondonInterbankOfferedRateLIBORMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.", "label": "London Interbank Offered Rate L I B O R [Member]", "terseLabel": "30-day LIBOR" } } }, "localname": "LondonInterbankOfferedRateLIBORMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureLongTermDebtNetOfDiscountsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": { "auth_ref": [ "r81", "r119" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureLongTermDebtNetOfDiscountsScheduleOfFuturePrincipalPaymentsOfLongTermDebtDetails": { "order": 10060.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long Term Debt Maturities Repayments Of Principal After Year Five", "terseLabel": "Thereafter" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureLongTermDebtNetOfDiscountsScheduleOfFuturePrincipalPaymentsOfLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": { "auth_ref": [ "r81", "r119" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureLongTermDebtNetOfDiscountsScheduleOfFuturePrincipalPaymentsOfLongTermDebtDetails": { "order": 10050.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long Term Debt Maturities Repayments Of Principal In Year Five", "terseLabel": "2023" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureLongTermDebtNetOfDiscountsScheduleOfFuturePrincipalPaymentsOfLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "auth_ref": [ "r81", "r119" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureLongTermDebtNetOfDiscountsScheduleOfFuturePrincipalPaymentsOfLongTermDebtDetails": { "order": 10040.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long Term Debt Maturities Repayments Of Principal In Year Four", "terseLabel": "2022" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureLongTermDebtNetOfDiscountsScheduleOfFuturePrincipalPaymentsOfLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "auth_ref": [ "r81", "r119" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureLongTermDebtNetOfDiscountsScheduleOfFuturePrincipalPaymentsOfLongTermDebtDetails": { "order": 10030.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long Term Debt Maturities Repayments Of Principal In Year Three", "terseLabel": "2021" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureLongTermDebtNetOfDiscountsScheduleOfFuturePrincipalPaymentsOfLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r81", "r119" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureLongTermDebtNetOfDiscountsScheduleOfFuturePrincipalPaymentsOfLongTermDebtDetails": { "order": 10020.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long Term Debt Maturities Repayments Of Principal In Year Two", "terseLabel": "2020" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureLongTermDebtNetOfDiscountsScheduleOfFuturePrincipalPaymentsOfLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": { "auth_ref": [ "r81" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureLongTermDebtNetOfDiscountsScheduleOfFuturePrincipalPaymentsOfLongTermDebtDetails": { "order": 10010.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year", "terseLabel": "2019" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureLongTermDebtNetOfDiscountsScheduleOfFuturePrincipalPaymentsOfLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r32" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureLongTermDebtNetOfDiscountsScheduleOfShortTermAndLongTermDebtObligationsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 10100.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long Term Debt Noncurrent", "terseLabel": "Long term debt, net of discount", "totalLabel": "Long-term debt, net of discount and current portion" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureLongTermDebtNetOfDiscountsScheduleOfShortTermAndLongTermDebtObligationsDetails", "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermInvestments": { "auth_ref": [ "r23" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 10180.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).", "label": "Long Term Investments", "terseLabel": "Long-term investments" } } }, "localname": "LongTermInvestments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermPurchaseCommitmentAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The minimum amount the entity agreed to spend under the long-term purchase commitment.", "label": "Long Term Purchase Commitment Amount", "terseLabel": "Long-term purchase commitment amount" } } }, "localname": "LongTermPurchaseCommitmentAmount", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by category of items purchased under a long-term purchase commitment.", "label": "Long Term Purchase Commitment By Category Of Item Purchased [Axis]", "terseLabel": "Category of Item Purchased" } } }, "localname": "LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "General description of the goods or services to be purchased from the counterparty to the long-term purchase commitment.", "label": "Long Term Purchase Commitment Category Of Item Purchased [Domain]", "terseLabel": "Long-term Purchase Commitment, Category of Item Purchased" } } }, "localname": "LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongtermPurchaseCommitmentPeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Period covered by the long-term purchase commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Longterm Purchase Commitment Period", "terseLabel": "Long-term purchase commitment period" } } }, "localname": "LongtermPurchaseCommitmentPeriod", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ManufacturingFacilityMember": { "auth_ref": [ "r111" ], "lang": { "en-US": { "role": { "documentation": "Structure used in the manufacturing of goods.", "label": "Manufacturing Facility [Member]", "terseLabel": "Manufacturing Facility" } } }, "localname": "ManufacturingFacilityMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r65" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 10030.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided By Used In Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided By Used In Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r65" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 10020.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided By Used In Investing Activities", "totalLabel": "Net cash provided by (used in) investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided By Used In Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r65", "r66", "r69" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 10010.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided By Used In Operating Activities", "negatedLabel": "Net cash used in operating activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails", "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided By Used In Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r46", "r48", "r52", "r69", "r88", "r257", "r268" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSUnaudited": { "order": 10010.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income Loss", "negatedLabel": "Net loss", "terseLabel": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails", "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSUnaudited", "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements Policy Policy [Text Block]", "terseLabel": "Recently Issued Accounting Pronouncements Not Yet Adopted" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number Of Reportable Segments", "terseLabel": "Number of reportable segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSUnaudited": { "order": 10070.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSUnaudited": { "order": 10050.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income Loss", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r216", "r222" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesComponentOfLeaseCostsIncludedInCondensedConsolidatedStatementsOfIncomeDetails": { "order": 10010.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease Cost", "terseLabel": "Operating lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesComponentOfLeaseCostsIncludedInCondensedConsolidatedStatementsOfIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r207" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails2": { "order": 10060.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease Liability", "terseLabel": "Operating lease, liability", "totalLabel": "Operating lease, Present value of lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails", "http://www.aimmune.com/20190630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r207" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": { "order": 10170.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 }, "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 10150.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease Liability Current", "negatedLabel": "Less: Operating lease, current portion", "terseLabel": "Operating lease liabilities, current" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails", "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r207" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": { "order": 10180.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 }, "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 10110.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease Liability Noncurrent", "terseLabel": "Operating lease, Long-term lease liabilities", "verboseLabel": "Operating lease liabilities, non-current" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails", "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r210", "r217" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease Payments", "terseLabel": "Operating cash flows from operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOtherInformationRelatedToOperatingLeaseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r206" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 10200.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease Right Of Use Asset", "terseLabel": "Operating lease, right-of-use asset", "verboseLabel": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r219", "r222" ], "lang": { "en-US": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease Weighted Average Discount Rate Percent", "terseLabel": "Operating Lease, Weighted-average incremental borrowing rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r218", "r222" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease Weighted Average Remaining Lease Term1", "terseLabel": "Operating Lease, Weighted-average remaining lease term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": { "auth_ref": [ "r201", "r202" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureAggregateMinimumLeasePaymentsCalculatedUnderASC840Details": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureAggregateMinimumLeasePaymentsCalculatedUnderASC840Details2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.", "label": "Operating Leases Future Minimum Payments Due", "totalLabel": "Operating Lease, Total lease payments" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureAggregateMinimumLeasePaymentsCalculatedUnderASC840Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears": { "auth_ref": [ "r201", "r202" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureAggregateMinimumLeasePaymentsCalculatedUnderASC840Details": { "order": 10210.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases Future Minimum Payments Due In Five Years", "terseLabel": "Operating Lease, 2023" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInFiveYears", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureAggregateMinimumLeasePaymentsCalculatedUnderASC840Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": { "auth_ref": [ "r201", "r202" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureAggregateMinimumLeasePaymentsCalculatedUnderASC840Details": { "order": 10200.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases Future Minimum Payments Due In Four Years", "terseLabel": "Operating Lease, 2022" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureAggregateMinimumLeasePaymentsCalculatedUnderASC840Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": { "auth_ref": [ "r201", "r202" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureAggregateMinimumLeasePaymentsCalculatedUnderASC840Details": { "order": 10190.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases Future Minimum Payments Due In Three Years", "terseLabel": "Operating Lease, 2021" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureAggregateMinimumLeasePaymentsCalculatedUnderASC840Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": { "auth_ref": [ "r201", "r202" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureAggregateMinimumLeasePaymentsCalculatedUnderASC840Details": { "order": 10180.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases Future Minimum Payments Due In Two Years", "terseLabel": "Operating Lease, 2020" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureAggregateMinimumLeasePaymentsCalculatedUnderASC840Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter": { "auth_ref": [ "r201", "r202" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureAggregateMinimumLeasePaymentsCalculatedUnderASC840Details": { "order": 10220.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases Future Minimum Payments Due Thereafter", "terseLabel": "Operating Lease, Thereafter" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueThereafter", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureAggregateMinimumLeasePaymentsCalculatedUnderASC840Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear": { "auth_ref": [], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureAggregateMinimumLeasePaymentsCalculatedUnderASC840Details": { "order": 10170.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases Future Minimum Payments Remainder Of Fiscal Year", "terseLabel": "Operating Lease, 2019" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureAggregateMinimumLeasePaymentsCalculatedUnderASC840Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Organization Consolidation And Presentation Of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r5", "r6", "r7", "r29" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails": { "order": 10040.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities Current", "terseLabel": "Other" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent [Abstract]", "terseLabel": "Other comprehensive loss, net of tax:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r40", "r42" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSUnaudited": { "order": 10020.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.", "label": "Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax", "terseLabel": "Unrealized gains (losses) on investments", "verboseLabel": "Other comprehensive gain (loss)" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSUnaudited", "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r4", "r5", "r29" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 10160.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities Current", "terseLabel": "Other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r33" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 10120.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities Noncurrent", "terseLabel": "Other liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "auth_ref": [ "r63" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 10050.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "Payments Of Debt Issuance Costs", "negatedLabel": "Debt issuance costs", "terseLabel": "Payment of fees including debt issuance costs" } } }, "localname": "PaymentsOfDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureLongTermDebtNetOfDiscountsAdditionalInformationDetails", "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r62", "r136" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 10080.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow to satisfy an employee's income tax withholding obligation as part of a net-share settlement of a share-based award.", "label": "Payments Related To Tax Withholding For Share Based Compensation", "negatedLabel": "Tax withholdings related to net share settlements of restricted stock units" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "auth_ref": [ "r56", "r58", "r103" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 10100.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Payments To Acquire Available For Sale Securities Debt", "negatedLabel": "Purchase of investments" } } }, "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r59" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 10090.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments To Acquire Property Plant And Equipment", "negatedLabel": "Purchase of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r140", "r171" ], "lang": { "en-US": { "role": { "documentation": "Information by plan name pertaining to equity-based compensation arrangements.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationRestrictedStockUnitActivityDetails", "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfUnrecognizedStockBasedCompensationExpenseAndExpectedPeriodDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the equity-based compensation arrangement plan.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationRestrictedStockUnitActivityDetails", "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfUnrecognizedStockBasedCompensationExpenseAndExpectedPeriodDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r13" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock Par Or Stated Value Per Share", "terseLabel": "Preferred stock, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r13" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock Shares Authorized", "terseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r13" ], "lang": { "en-US": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock Shares Issued", "terseLabel": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r13" ], "lang": { "en-US": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r13" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 10040.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock Value", "terseLabel": "Preferred stock, par value $0.0001 per share\u2014 10,000 shares authorized at June 30, 2019 and December 31, 2018; 0 shares issued and outstanding at June 30, 2019 and December 31, 2018" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r2", "r20", "r21" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 10240.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense And Other Assets Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent": { "auth_ref": [ "r10", "r249", "r261" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 10210.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed after one year or the normal operating cycle, if longer.", "label": "Prepaid Expense And Other Assets Noncurrent", "terseLabel": "Prepaid expenses and other assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r60" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 10060.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds From Issuance Of Common Stock", "terseLabel": "Proceeds from underwritten public offering, net of offering costs" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "auth_ref": [ "r61" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 10040.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.", "label": "Proceeds From Issuance Of Long Term Debt", "terseLabel": "Borrowings under debt agreement" } } }, "localname": "ProceedsFromIssuanceOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": { "auth_ref": [ "r57" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 10110.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.", "label": "Proceeds From Sale Maturity And Collections Of Investments", "terseLabel": "Maturities of investments" } } }, "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r60", "r172" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 10070.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from exercise of stock options granted under share-based compensation arrangement.", "label": "Proceeds From Stock Options Exercised", "terseLabel": "Net cash proceeds from exercise of stock options, including early exercise" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r46", "r48", "r64", "r99", "r100", "r180", "r182", "r183", "r185", "r186" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 10120.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Profit Loss", "terseLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Property Plant And Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r25", "r113" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Property Plant And Equipment By Type [Axis]", "terseLabel": "Property, Plant and Equipment, Type" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails", "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r24", "r111" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails": { "order": 10010.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property Plant And Equipment Gross", "terseLabel": "Property and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property Plant And Equipment [Line Items]", "terseLabel": "Property Plant And Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r8", "r9", "r113", "r265" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 10190.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property Plant And Equipment Net", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails", "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r8", "r113" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property Plant And Equipment [Text Block]", "terseLabel": "Summary of Property And Equipment, Net" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r8", "r111" ], "lang": { "en-US": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Property Plant And Equipment Type [Domain]", "terseLabel": "Property, Plant and Equipment, Type" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails", "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r230" ], "lang": { "en-US": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureRelatedPartyTransactionAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "auth_ref": [ "r223", "r226", "r227" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of transactions with related party during the financial reporting period.", "label": "Related Party Transaction Amounts Of Transaction", "terseLabel": "Payments to service agreement" } } }, "localname": "RelatedPartyTransactionAmountsOfTransaction", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureRelatedPartyTransactionAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureRelatedPartyTransactionAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r134", "r225", "r226", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247" ], "lang": { "en-US": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party Transactions By Related Party [Axis]", "terseLabel": "Related Party" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureRelatedPartyTransactionAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r230" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related Party Transaction" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureRelatedPartyTransaction" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r178", "r270" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSUnaudited": { "order": 10080.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research And Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research And Development Expense [Member]", "terseLabel": "Research and Development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseNetOfEstimatedForfeituresDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r87" ], "lang": { "en-US": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Restricted Stock" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseRecognizedDetails", "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units R S U [Member]", "terseLabel": "Restricted Stock Units (RSUs)", "verboseLabel": "RSUs" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails", "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationRestrictedStockUnitActivityDetails", "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfUnrecognizedStockBasedCompensationExpenseAndExpectedPeriodDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r16", "r129", "r263" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 10080.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings Accumulated Deficit", "negatedLabel": "Accumulated deficit", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails", "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale Of Stock Name Of Transaction [Domain]", "terseLabel": "Sale of Stock" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfWeightedAverageAssumptionsToFairValueOfStockOptionsDetails", "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "domainItemType" }, "us-gaap_ScenarioForecastMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The reporting scenario used to indicate financial results forecast for a future period.", "label": "Scenario Forecast [Member]", "terseLabel": "Scenario, Forecast" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureLongTermDebtNetOfDiscountsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScenarioUnspecifiedDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Any scenario, that is, the particular reporting scenario is left unspecified. Scenarios distinguish among different kinds of business reporting facts, as for example actual versus budgeted figures.", "label": "Scenario Unspecified [Domain]", "terseLabel": "Scenario, Unspecified" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureLongTermDebtNetOfDiscountsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule Of Accrued Liabilities Table [Text Block]", "terseLabel": "Summary of Accrued Liabilities" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r87" ], "lang": { "en-US": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]", "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r87" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Diluted Net Loss per Share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureNetLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.", "label": "Schedule Of Available For Sale Securities Reconciliation Table [Text Block]", "terseLabel": "Summary of Aggregate Market Value, Cost Basis and Gross Unrealized Gains and Losses of Available-for-Sale Investments by Security Type" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureAvailableForSaleSecuritiesAndFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "Schedule Of Debt Table [Text Block]", "terseLabel": "Schedule of Short-term and Long-term Debt Obligations" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureLongTermDebtNetOfDiscountsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r139", "r168", "r174" ], "lang": { "en-US": { "role": { "documentation": "Schedule that sets forth the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.", "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]", "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseNetOfEstimatedForfeituresDetails", "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseRecognizedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r139", "r168", "r174" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.", "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]", "terseLabel": "Summary of Stock-based Compensation Expense" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "auth_ref": [ "r119" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the combined aggregate amount of maturities and sinking fund requirements for all long-term borrowings for each of the five years following the date of the latest balance sheet date presented.", "label": "Schedule Of Maturities Of Long Term Debt Table [Text Block]", "terseLabel": "Schedule of Future Principal Payments of Long-term Debt" } } }, "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureLongTermDebtNetOfDiscountsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r25", "r113" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Schedule Of Property Plant And Equipment [Table]", "terseLabel": "Schedule Of Property Plant And Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r77", "r225", "r226", "r227", "r228", "r229" ], "lang": { "en-US": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule Of Related Party Transactions By Related Party [Table]", "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureRelatedPartyTransactionAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": { "auth_ref": [ "r154", "r159", "r161" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure for share-based compensation plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Schedule Of Share Based Compensation Activity Table [Text Block]", "terseLabel": "Summary of Stock Option Activity" } } }, "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r140", "r171" ], "lang": { "en-US": { "role": { "documentation": "Components of an equity-based arrangement under which compensation is awarded to employees, typically comprised of compensation expense; changes in the quantity and fair value of the shares (or other type of equity) granted, exercised, forfeited, and issued and outstanding pertaining to that plan; and cash flow effects resulting from the equity-based payment arrangement. Component disclosures are by type of award and plan name.", "label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]", "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationRestrictedStockUnitActivityDetails", "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfWeightedAverageAssumptionsToFairValueOfStockOptionsDetails", "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfUnrecognizedStockBasedCompensationExpenseAndExpectedPeriodDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "auth_ref": [ "r146" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.", "label": "Schedule Of Share Based Compensation Restricted Stock Units Award Activity Table [Text Block]", "terseLabel": "Restricted Stock Unit Activity" } } }, "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": { "auth_ref": [ "r163" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule Of Share Based Payment Award Employee Stock Purchase Plan Valuation Assumptions Table [Text Block]", "terseLabel": "Schedule of Weighted Average Assumptions to Fair Value of Stock Options" } } }, "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock": { "auth_ref": [ "r170" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the total compensation cost related to nonvested awards not yet recognized and the weighted-average period over which it is expected to be recognized.", "label": "Schedule Of Unrecognized Compensation Cost Nonvested Awards Table [Text Block]", "terseLabel": "Summary of Unrecognized Stock-Based Compensation Expense and Expected Period" } } }, "localname": "ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r67" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 10140.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.", "label": "Share Based Compensation", "terseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share Based Compensation Allocation And Classification In Financial Statements [Abstract]" } } }, "localname": "ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Additional share-based compensation cost recognized as a result of an occurrence of an event that accelerates its recognition.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Accelerated Compensation Cost", "terseLabel": "Accelerated stock compensation expense" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r142" ], "lang": { "en-US": { "role": { "documentation": "Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1", "terseLabel": "Options vesting period", "verboseLabel": "Long-term purchase commitment, shares issued, vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription": { "auth_ref": [ "r138", "r141" ], "lang": { "en-US": { "role": { "documentation": "General descriptive information regarding an arrangement under which employees and directors receive: (a) awards of equity shares, equity share options, or other equity instruments; or (b) the entity incurs liabilities to them: (1) in amounts based, at least in part, on the price of the entity's shares or other equity instruments; or (2) that require or may require settlement by issuance of the entity's shares. Such an arrangement is usually provided to employees and directors to compensate them, provide performance incentives to them, and to attract or retain their services. May also include pertinent information particular to a plan that is not elsewhere specified in the taxonomy.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Description", "terseLabel": "Description of ESPP" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r152" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period", "negatedLabel": "Shares, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationRestrictedStockUnitActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r158" ], "lang": { "en-US": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value", "terseLabel": "Weighted Average Grant Date Fair Value, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationRestrictedStockUnitActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r156" ], "lang": { "en-US": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period", "verboseLabel": "Shares, Awarded" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationRestrictedStockUnitActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r156" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value", "terseLabel": "Weighted Average Grant Date Fair Value, Awarded" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationRestrictedStockUnitActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r155" ], "lang": { "en-US": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number", "periodEndLabel": "Unvested Shares, Ending Balance", "periodStartLabel": "Unvested Shares, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationRestrictedStockUnitActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r155" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value", "periodEndLabel": "Weighted Average Grant Date Fair Value, Ending Balance", "periodStartLabel": "Unvested Weighted Average Grant Date Fair Value, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationRestrictedStockUnitActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r157" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period", "negatedLabel": "Shares, Released" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationRestrictedStockUnitActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r157" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value", "terseLabel": "Weighted Average Grant Date Fair Value, Released" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationRestrictedStockUnitActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions And Methodology [Abstract]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r166" ], "lang": { "en-US": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate", "terseLabel": "Dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfWeightedAverageAssumptionsToFairValueOfStockOptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r165" ], "lang": { "en-US": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate", "terseLabel": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfWeightedAverageAssumptionsToFairValueOfStockOptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r167" ], "lang": { "en-US": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate", "terseLabel": "Risk free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfWeightedAverageAssumptionsToFairValueOfStockOptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]", "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationRestrictedStockUnitActivityDetails", "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfWeightedAverageAssumptionsToFairValueOfStockOptionsDetails", "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfUnrecognizedStockBasedCompensationExpenseAndExpectedPeriodDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r171" ], "lang": { "en-US": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant", "terseLabel": "Number of shares available for future grant" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Additional Disclosures [Abstract]", "terseLabel": "Weighted Average Remaining Contractual Life (in years)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r149" ], "lang": { "en-US": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number", "terseLabel": "Number of Options, Options exercisable as of June 30, 2019" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r149" ], "lang": { "en-US": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price", "terseLabel": "Weighted-Average Exercise Price, Options exercisable as of June 30, 2019" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r153" ], "lang": { "en-US": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price", "terseLabel": "Weighted-Average Exercise Price, Options cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r152" ], "lang": { "en-US": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period", "negatedLabel": "Number of Options, Options cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross", "verboseLabel": "Number of Options, Options granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r160" ], "lang": { "en-US": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average estimated fair value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfWeightedAverageAssumptionsToFairValueOfStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r171" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r148", "r171" ], "lang": { "en-US": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number", "periodEndLabel": "Number of Options, Ending Balance", "periodStartLabel": "Number of Options, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Roll Forward", "terseLabel": "Number of Options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r147" ], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price", "periodEndLabel": "Weighted-Average Exercise Price, Ending Balance", "periodStartLabel": "Weighted-Average Exercise Price, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Rollforward", "terseLabel": "Weighted-Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r161" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Options vested and expected to vest as of June 30, 2019" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r162" ], "lang": { "en-US": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number", "terseLabel": "Number of Options, Options vested and expected to vest as of June 30, 2019" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r162" ], "lang": { "en-US": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price", "terseLabel": "Weighted-Average Exercise Price, Options vested and expected to vest as of June 30, 2019" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased": { "auth_ref": [ "r138", "r171" ], "lang": { "en-US": { "role": { "documentation": "The weighted average of per share prices paid for shares purchased on the open market for issuance to employees under the plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Per Share Weighted Average Price Of Shares Purchased", "terseLabel": "Weighted average price per share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": { "auth_ref": [ "r171" ], "lang": { "en-US": { "role": { "documentation": "Number of share instruments newly issued under a share-based compensation plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period", "terseLabel": "Shares issued under the plan" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r138", "r145" ], "lang": { "en-US": { "role": { "documentation": "Equity-based compensation award.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]", "terseLabel": "Equity Award" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationRestrictedStockUnitActivityDetails", "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseRecognizedDetails", "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfUnrecognizedStockBasedCompensationExpenseAndExpectedPeriodDetails", "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price", "terseLabel": "Weighted-Average Exercise Price, Options granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "First portion of share-based compensation award differentiated by a particular vesting feature, including, but not limited to, performance measure or service period.", "label": "Share Based Compensation Award Tranche One [Member]", "terseLabel": "First Anniversary" } } }, "localname": "ShareBasedCompensationAwardTrancheOneMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Third portion of share-based compensation award differentiated by a particular vesting feature, including, but not limited to, performance measure or service period.", "label": "Share Based Compensation Award Tranche Three [Member]", "terseLabel": "Over Two Years" } } }, "localname": "ShareBasedCompensationAwardTrancheThreeMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Second portion of share-based compensation award differentiated by a particular vesting feature, including, but not limited to, performance measure or service period.", "label": "Share Based Compensation Award Tranche Two [Member]", "terseLabel": "Thereafter" } } }, "localname": "ShareBasedCompensationAwardTrancheTwoMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued": { "auth_ref": [ "r130", "r150" ], "lang": { "en-US": { "role": { "documentation": "The number of shares or units of entity securities issued in the transaction in which equity securities were issued to pay for goods or nonemployee services.", "label": "Share Based Goods And Nonemployee Services Transaction Quantity Of Securities Issued", "verboseLabel": "Stock-based compensation, shares vested" } } }, "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance": { "auth_ref": [ "r130", "r144" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of shares (or other type of equity) that have been approved for issuance in the equity-based payment transaction.", "label": "Share Based Goods And Nonemployee Services Transaction Shares Approved For Issuance", "terseLabel": "Long-term purchase commitment, shares issued" } } }, "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionStockholdersEquity": { "auth_ref": [ "r130", "r171" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount by which stockholders' equity was increased by the transaction in which equity securities were issued to pay for goods or nonemployee services.", "label": "Share Based Goods And Nonemployee Services Transaction Stockholders Equity", "terseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseRecognizedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "auth_ref": [ "r142" ], "lang": { "en-US": { "role": { "documentation": "Percentage of vesting of share-based compensation awards.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage", "terseLabel": "Option vesting rights, percentage" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r143" ], "lang": { "en-US": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period", "terseLabel": "Options expiration period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r164", "r173" ], "lang": { "en-US": { "role": { "documentation": "Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1", "terseLabel": "Expected term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfWeightedAverageAssumptionsToFairValueOfStockOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r171" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1", "terseLabel": "Aggregate Intrinsic Value, Options exercisable as of June 30, 2019" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r171" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1", "terseLabel": "Weighted Average Remaining Contractual Life, Options exercisable as of June 30, 2019" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r162" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2", "terseLabel": "Weighted Average Remaining Contractual Life (in years), Balance" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r162" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1", "terseLabel": "Weighted Average Remaining Contractual Life, Options vested and expected to vest as of June 30, 2019" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Purchase price of common stock expressed as a percentage of its fair value.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent", "terseLabel": "Percentage of statutory stock options" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares Outstanding", "periodEndLabel": "Ending balances (in shares)", "periodStartLabel": "Beginning balances (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r82" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r36", "r124" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Statement Equity Components [Axis]", "terseLabel": "Equity Components" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseRecognizedDetails", "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationTables", "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement Of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement Of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement Of Income And Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementScenarioAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by scenario to be reported. Scenarios distinguish among different kinds of business reporting facts, as for example actual versus budgeted figures.", "label": "Statement Scenario [Axis]", "terseLabel": "Scenario" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureLongTermDebtNetOfDiscountsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationTables", "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r13", "r14", "r124", "r129" ], "lang": { "en-US": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period Shares Employee Stock Purchase Plans", "terseLabel": "Employee stock purchase plan remain available for purchase" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r13", "r14", "r124", "r129" ], "lang": { "en-US": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period Shares New Issues", "terseLabel": "Issuance common stock upon initial public offering (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "auth_ref": [ "r124", "r129" ], "lang": { "en-US": { "role": { "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.", "label": "Stock Issued During Period Shares Restricted Stock Award Gross", "terseLabel": "Number of restricted stock issued" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r13", "r14", "r124", "r129", "r151" ], "lang": { "en-US": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Stock Issued During Period Shares Stock Options Exercised", "terseLabel": "Issuance of common stock upon exercise of vested options (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r13", "r14", "r124", "r129" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period Value New Issues", "terseLabel": "Issuance of common stock upon public offering" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r36", "r124", "r129" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period Value Stock Options Exercised", "terseLabel": "Issuance of common stock upon exercise of vested options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r14", "r17", "r18", "r101" ], "calculation": { "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 10030.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders Equity", "periodEndLabel": "Ending balances", "periodStartLabel": "Beginning balance", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders Equity [Abstract]", "terseLabel": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Subsidiary Sale Of Stock [Axis]", "terseLabel": "Sale of Stock" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfWeightedAverageAssumptionsToFairValueOfStockOptionsDetails", "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "auth_ref": [ "r39" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "terseLabel": "Balance Sheet Components" } } }, "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureBalanceSheetComponents" ], "xbrltype": "textBlockItemType" }, "us-gaap_TitleOfIndividualAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by title of individual or nature of relationship to individual or group of individuals.", "label": "Title Of Individual [Axis]", "terseLabel": "Title of Individual" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Title of individual, or nature of relationship to individual or group of individuals.", "label": "Title Of Individual With Relationship To Entity [Domain]", "terseLabel": "Relationship to Entity" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r235" ], "lang": { "en-US": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain]", "terseLabel": "Financial Instruments" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureAvailableForSaleSecuritiesAndFairValueMeasurementsSummaryOfAggregateMarketValueCostBasisAndGrossUnrealizedGainsAndLossesOfAvailableForSaleInvestmentsBySecurityTypeDetails", "http://www.aimmune.com/20190630/taxonomy/role/DisclosureAvailableForSaleSecuritiesAndFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Adoption and early adoption of sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues Accounting Standards Updates to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.", "label": "Type Of Adoption [Member]", "terseLabel": "Type of Adoption" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "auth_ref": [ "r132", "r253" ], "lang": { "en-US": { "role": { "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).", "label": "U S Government Agencies Debt Securities [Member]", "terseLabel": "Agency Securities" } } }, "localname": "USGovernmentAgenciesDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureAvailableForSaleSecuritiesAndFairValueMeasurementsSummaryOfAggregateMarketValueCostBasisAndGrossUnrealizedGainsAndLossesOfAvailableForSaleInvestmentsBySecurityTypeDetails", "http://www.aimmune.com/20190630/taxonomy/role/DisclosureAvailableForSaleSecuritiesAndFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember": { "auth_ref": [ "r132", "r253" ], "lang": { "en-US": { "role": { "documentation": "Debentures, bonds and other debt securities issued by US government sponsored entities (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). Excludes debt issued by the Government National Mortgage Association (GNMA or Ginnie Mae).", "label": "U S Government Sponsored Enterprises Debt Securities [Member]", "terseLabel": "U.S. Government Securities" } } }, "localname": "USGovernmentSponsoredEnterprisesDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureAvailableForSaleSecuritiesAndFairValueMeasurementsSummaryOfAggregateMarketValueCostBasisAndGrossUnrealizedGainsAndLossesOfAvailableForSaleInvestmentsBySecurityTypeDetails", "http://www.aimmune.com/20190630/taxonomy/role/DisclosureAvailableForSaleSecuritiesAndFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r90", "r91", "r92", "r93", "r94", "r95", "r96" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use Of Estimates", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureLongTermDebtNetOfDiscountsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureLongTermDebtNetOfDiscountsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_VestingAxis": { "auth_ref": [ "r171" ], "lang": { "en-US": { "role": { "documentation": "Information by vesting schedule for share-based compensation.", "label": "Vesting [Axis]", "terseLabel": "Vesting" } } }, "localname": "VestingAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VestingDomain": { "auth_ref": [ "r171" ], "lang": { "en-US": { "role": { "documentation": "Vesting schedule for share-based compensation.", "label": "Vesting [Domain]", "terseLabel": "Vesting" } } }, "localname": "VestingDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted Average Number Of Share Outstanding Basic And Diluted", "terseLabel": "Weighted average shares used in computing net loss per common share, basic and diluted" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.aimmune.com/20190630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSUnaudited" ], "xbrltype": "sharesItemType" } }, "unitCount": 6 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=109979856&loc=d3e26610-111562" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=109979856&loc=d3e26853-111562" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=109979856&loc=d3e26626-111562" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "8A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=109979856&loc=SL6284422-111562" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r115": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14326-108349" }, "r117": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6036836-161870" }, "r123": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=68057994&loc=d3e25284-112666" }, "r131": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/subtopic&trid=2208855" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=112275985&loc=d3e4179-114921" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "19A", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=107668666&loc=SL79513924-113897" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=79507207&loc=d3e4534-113899" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)-(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=SL79508275-113901" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109196918&loc=d3e11149-113907" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109196918&loc=d3e11178-113907" }, "r177": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=84234705&loc=SL4591551-111686" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=84234705&loc=SL4591552-111686" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3A-02)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=27015204&loc=d3e355033-122828" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3A-03)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=27015204&loc=d3e355100-122828" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19190-110258" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=109250915&loc=d3e13467-108611" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=109250915&loc=d3e13476-108611" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(Note 3)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=84164758&loc=d3e45023-112735" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=84164817&loc=d3e45280-112737" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=113997351&loc=SL77916155-209984" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918638-209977" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=68078379&loc=d3e122625-111746" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6)(a)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(3),(4))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "e", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.17)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r271": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r272": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "a", "Publisher": "SEC", "Section": "303", "Subparagraph": "5" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6801-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r39": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "210", "URI": "http://asc.fasb.org/topic&trid=2122208" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6904-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e637-108580" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e681-108580" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669686-108580" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL34724394-108580" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6911-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e557-108580" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3151-108585" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3179-108585" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6935-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3000-108585" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e7018-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3044-108585" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04.(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690" }, "r82": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r89": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r97": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" } }, "version": "2.1" }